

Title: Preventive interventions for post Covid-19 condition: systematic review update

Authors: Jennifer Pillay (Corresponding author), Sholeh Rahman, Nicole Gehring, Samantha Guitard, Ashiqur Rahman Ashiq, Lisa Hartling

Supplementary file.**Table of Contents**

Table S1. Characteristics table of included studies.....	2
Table S2. Quality assessment of the included cohort studies	20
Table S3: Quality assessment of the included randomized trials.....	26
Table S4. Summary of findings for secondary outcomes, by intervention	29
Table S5. Subgroup data for post-COVID-19 condition.....	40
Table S6. Subgroup data, secondary outcomes.....	44
Figure S1. PCC by antibiotic use.....	46
Figure S2. PCC by antibiotic use (sensitivity analysis, excluding non-recovery study [Evans 2021]).....	46
Figure S3. Fatigue by antiviral use	47
Figure S4. Fatigue by steroid use.....	47
Figure S5. Fatigue by steroid use (continuous)	47
Figure S6. Breathlessness/Dyspnea by steroid use.....	48
Figure S7. Cognitive impairment by antiviral use.....	48
Figure S8. Health-related quality of life by steroid use.....	48
Table S7. Search for Medline [Ovid]	49
Table S8. Search from Embase [Ovid].....	62
Table S9. Legend for database searches	77

Table S1. Characteristics table of included studies

First Author, Year; Country; Study Design [†] ; Timing of Infection	Type of Acute Care Average age (years); % Female; % Vaccinated	Intervention/Exposure Group (IG): Description & Timing	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
Recruitment setting and participant eligibility	COVID-19 Illness Severity	Control Group (CG)		
Risk of bias for primary outcome	Eligible Population All Having Post-acute Symptoms (Y/N)	N analyzed/enrolled		
Outpatients/mixed population with treatment initiated in acute phase				
Kolesnyk, 2024 Ukraine RCT November 2021 to June 2022 General population in primary care and outpatient practices; 18–65-year-old men or non-pregnant women with symptomatic COVID-19 lasting no longer than 5 days and confirmed by antigen or PCR testing ROB: Low	Outpatients (0% hospitalized) Median 45.0; 53%; NR Mild-to-moderate N	IG: Dietary supplement with probiotics (1 pill / day x 28 days); ≤5 days after positive test (n=34/36) CG: Placebo (n=35/37) * Other medication received during acute phase in both groups included: NSAIDs, Antitussives, Nasal decongestants, Throat antiseptics, Antispasmodics (only in the placebo group), Antidiarrheal, Antiplatelet, herbs Total: 69 analyzed/73 randomized	Post-COVID Functional Scale (PCFS) range 0-4; 13 weeks after COVID-19 positivity Score 0 (absence of any functional limitation): IG: 29/34 (85.3%) CG: 19/35 (54.3%) P=0.008 None	Fatigue (single item) Cognitive impairment (attention deficit, single item) Psychopathology (average of anxiety and depression, single items) Any adverse event (withdrawals due to AEs)
Rocha, 2023 Brazil Retrospective cohort	Outpatients (0% hospitalized) NR; 59%; NR	IG: Remained physically active (≥150 mins/week) after COVID-19 (n=388/NR)	Symptom checklist (≥1 symptom of 19 [not necessarily absent before COVID-19] focused on physical symptoms); 6–10 months after positive test	Fatigue (single item) Breathlessness/Dyspnea (dyspnea, single item) Cognitive impairment (average of memory loss)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
December 2020 to March 2021 ≥18-year old Brazilian participants who received a COVID-19 diagnosis through RT-PCR testing, experienced COVID-19 symptoms, and received medical care in Rio Grande ROB: High	Mild-to-moderate N	CG1: Became physically inactive after COVID-19 (n=435/NR) CG2: Remained physically inactive (n=2,096/NR) Total: 823 analyzed in comparison of interest (2,919 analyzed overall)/3,550 eligible	IG: 142/388 (36.5%) CG1: 226/435 (51.9%) CG2: 1,041/2,096 (49.7%) IG vs. CG1: aPR NR Additional analyses (not of interest): IG vs. CG2: aPR 0.80 (0.63, 0.99) CG1 vs. CG2: aPR 0.97 (0.80, 1.17) None	and attention loss, single items)
Gebo, 2023 US Secondary analysis of a double- blind RCT (75% of original sample) June 2020 to October 2021 Symptomatic adult outpatients (≥18 years old) with acute SARS- CoV-2 infection from 23 sites. Analysis restricted to those with blood drawn at screening, day 14, and day 90, and complete symptom data on day 90	Outpatients (0% hospitalized) Median 43.0; 57.4%; 15.8% and 6.2% fully and partially vaccinated Mild-to-moderate N	IG: COVID-19 convalescent plasma (CCP); ≤9 days of symptom onset (n=445/592) CG: Control plasma; ≤9 days of symptom onset (n=437/589) Total: 882 analyzed/1,225 randomized	Symptom checklist (≥1 symptom of 17) at 90 days post- transfusion Among those with 90 days symptom data and blood samples: IG: 142/445 (31.9%) CG: 150/437 (34.3%) Subgroups: by timing of receiving convalescent plasma	None

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: Low				
Durstenfeld, 2023 US Prospective matched cohort March to August 2022 Vaccinated, non-hospitalized, nonpregnant adults (≥ 18 years old) who were registered in an online cohort study (COVID-19 Citizen Science). Outcomes were ascertained only for those who responded to surveys about Long COVID symptoms in November and December 2022	Outpatients (0% hospitalized) Median 55.0; 66%; 100% Mild-to-moderate, but eligible for antivirals N	IG: Oral nirmatrelvir/ritonavir; ≤ 30 days of positive test (n=353/988) CG: No exposure, not all eligible/high-risk (n=1,258/3,696) Total: 1,611 analyzed/4,684 enrolled	Symptom checklist (≥ 1 symptom of 19 plus "other"); 5.4 ± 1.3 months after infection IG: 57/353 (16.1%) CG: 176/1,258 (14.0%) Propensity-score adjusted (and adjusted for additional factors) aOR: 1.17 (0.81, 1.69) Propensity-score adjusted aOR: 1.15 (0.80, 1.64); P=0.45 Analysis restricted to those at high-risk for severe infection i.e. eligible for treatment, by sensitive definition (n=968 treated and n=3326 untreated): OR: 1.11 (0.77, 1.59) by specific definition (n=890 treated and n=2,840): OR: 1.12 (0.78, 1.60) Analysis among those at high risk for severe COVID-19 (propensity-matching): 0.032 (-0.017, 0.081); P=0.20	None
ROB: High				

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
			10.5% vs. 10.2% reported 1+ severe PCC symptom	
Congdon, 2023 US Retrospective cohort January to July 2022 Adult COVID-19 patients ≥18 years old who met the criteria to be prescribed nirmatrelvir/ritonavir under the Food and Drug Administration's EUA ROB: Some concerns	Outpatients (1% hospitalized) Mean 50.6 (SD: 15.2); 70%; 67.6% primary series+booster, 24.6% primary series alone Mild-to-severe, but eligible for antivirals N	IG: Nirmatrelvir/ritonavir full/partial dose (out of 10 total doses) received during acute infection (n=250) CG: No exposure, but eligible (n=250) Total: 500 analyzed/500 enrolled	Symptom checklist (≥1 new or worsened symptoms of 11); 4 months (120-150 days) after positive test IG: 110/250 (44%) CG: 125/250 (50%) aOR: 0.83 (0.57, 1.2), P=0.31 None	Fatigue (generalized fatigue, single item) Breathlessness/Dyspnea (dyspnea, single item) Cognitive impairment (brain fog, single item)
Bertuccio, 2023 Italy Retrospective cohort April 2021 to March 2022 (94.3% during Omicron) Outpatient adults (>18 years old) with a positive SARS-CoV-2 nasopharyngeal swab and mild-to-moderate COVID-19 within the prior 5 (for oral antivirals) or 7 (for intravenous short-course remdesivir or mAbs) days; and	Outpatients (0% hospitalized) Median 67.0 (IQR 54–76); 48.4%; 81.3% with ≥ 2 doses Mild-to-moderate, but all having ≥ 1 risk factor for severe illness N	IG1: Anti-SARS-CoV-2 monoclonal antibodies (bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab), ≤7 days of symptom onset (n=141) IG2: Oral antivirals (nirmatrelvir/ritonavir, molnupiravir, or short-course remdesivir); ≤5-7 days of symptom onset (n=77) CG: patients eligible for IG1 or IG2 who refused treatment (n=105)	CDC symptom list (≥1 symptom, unclear if present before COVID-19), 3 months post symptom-onset IG1: 42/141 (29.8%) IG2: 16/77 (20.8%) CG: 36/105 (34.3%) IG1 vs. CG: aOR 0.78 (0.44, 1.36) IG2: vs. CG: aOR 0.43 (0.21, 0.87)	None

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
reported presence of at least one risk factors for COVID-19 progression ROB: High		Total: 323 analyzed/649 enrolled	Sensitivity analysis did not show any differences between the three periods, where prevalent variants were respectively Alpha, Delta and Omicron (data not shown).	
Patel, 2024 US (TriNetX) Retrospective matched cohort December 2021- December 2022 Non-hospitalized, vaccinated adult patients (≥ 18 years old) with preexisting CVD (i.e., presence of ≥ 1 comorbidity including hypertension, hyperlipidemia, type 2 diabetes mellitus, ischemic heart disease, cerebrovascular disease, cardiomyopathy/heart failure, arrhythmia) who were vaccinated and subsequently developed COVID-19 ROB: Some concerns	Outpatients (0% hospitalized) Mean 62.4 (SD: 14.5); 61%; 100% Mild-to-moderate N	IG: Nirmatrelvir-ritonavir, ≤ 5 days of diagnosis (n=26,593) CG: No exposure (n=26,593), not all eligible Total: 53,186 analyzed/53,186 enrolled	≥ 1 symptom based on the CDC and WHO definition (included a list of the constitutional, cardio-respiratory, gastrointestinal, musculoskeletal, and nervous system, and/or mood/cognitive disorder symptoms), 90-180 days post index infection IG: 6,692/26,593 (25.1%) CG: 8,910/26,593 (33.5%) Propensity score matching OR: 0.67 (0.64, 0.69); P < 0.001	Psychopathology (Anxiety/mood disorders, ICD codes)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
Chuang, 2023 Taiwan (TriNetX) Retrospective matched cohort January 1 and July 31, 2022 Adult population (>18 years old) with more than two visits to Health Care Organizations (HCOs) that tested SARS-CoV-2 ROB: Low	Outpatients (0% hospitalized) Mean 56.0; 57.3%; NR NR N	IG: Nirmatrelvir plus ritonavir, ≤5 days of diagnosis (n=12,245) CG: No exposure (n=12,245), not all eligible Total: 24,490 analyzed/24,490 enrolled	Overlapping population with Patel 2024, thus used for the subgroup data for the primary outcome and secondary outcomes Subgroups: age, sex, and vaccination status (i.e., none vs. ≥1 dose >2 weeks before the diagnosis of COVID-19)	Fatigue (ICD codes) Cognitive impairment (ICD codes) Psychopathology (anxiety/depression, single item, used Patel 2024 data) Hospitalization (all- cause hospitalizations, ICD codes; ER visits)
Bramante, 2023 US RCT (factorial design 2x3) December 2020 to January 2022 Adults 30-85 years old with overweight or obesity (BMI ≥25 kg/m ² or ≥23 kg/m ² for people identifying as Asian or Latino) who had COVID-19 symptoms for fewer than 7 days and confirmed COVID-19 infection within 3 days before enrolment, with no known previous SARS-CoV-2 infection	Outpatients (0% hospitalized) Median 45.0 (IQR 37–54); 56.1%; 55% with primary series Symptomatic N	IG1: Metformin+placebo (n=221) IG2: Ivermectin+placebo (n=189) IG3: Fluvoxamine+placebo (n=144) IG1+IG2 (n=189) IG1+IG3 (n=154) CG: Matched placebo for each drug (n=229 for IG1, 185 for IG2, 152 for IG3, 189 for IG1+IG2, 144 for IG1+IG3) all ≤7 days after symptom onset	Self-reported diagnosis of PCC by medical provider (with EHR confirmation), diagnoses 10 months (300 days) from randomization Crude data for single drugs + placebo chosen over main analysis in paper: IG1 vs. CG1: 11/221 (5.0%) vs. 23/229 (10.0%) IG2 vs. CG2: 18/189 (9.5%) vs. 19/185 (10.3%) IG3 vs. CG3: 17/144 (11.8%) vs. 14/152 (9.2%)	Serious AEs (self-report in diaries)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: Some concerns		<p>*Every participant received a pill that looked like metformin (either active metformin or exact-matching metformin placebo). For combination of interventions, the second pill was either ivermectin or exact-matching ivermectin placebo; or fluvoxamine or exact-matching fluvoxamine placebo.</p> <p>Total: 1,126 analyzed/1,323 enrolled in mITT analysis (1,431 originally randomized)</p>	<p>IG1+IG2 vs. CG: 11/189 (5.8%) vs. 18/189 (9.5%)</p> <p>IG1+IG3 vs. CG: 13/154 (8.4%) vs. 17/144 (11.8%)</p> <p>Main analysis from paper:</p> <p>Metformin vs. placebo: aHR: 0.599 (0.39, 0.91)</p> <p>Ivermectin vs. placebo: aHR: 0.952 (0.571, 1.587)</p> <p>Fluvoxamine vs. placebo: aHR: 1.346 (0.776, 2.335)</p> <p>Subgroups (available for the first three main analyses from the paper): sex, age group (<45 vs. ≥45y), timing of the first dose of IG (≤3 vs ≥4 days from symptom onset), SARS variants, vaccination status</p>	
Hospitalized population with treatment initiated in acute phase				
Darcis, 2021 Belgium Retrospective cohort March to October 2020 (discharge date)	<p>Hospitalized (26% ICU admission)</p> <p>Mean 60.5 (SD: 13.9); 36.7%; NR</p> <p>Moderate-to-severe</p>	<p>IG1: Hydroxychloroquine (n=88)</p> <p>IG2: Corticosteroids (n=25)</p> <p>IG3: Antibiotics (n=98)</p> <p>IG4: Platelet antiaggregants (n=24)</p> <p>Timing NR</p>	<p>≥1 persistent symptom (from a list of 20 symptoms), 3 months post-discharge</p> <p>IG1 vs. CG1: 61/88 (69.3%) vs. 10/13 (76.9%)</p> <p>IG2 vs. CG2: 19/25 (76.0%) vs. 52/76 (68.4%)</p> <p>IG3 vs. CG3: 70/98 (71.4%) vs. 1/3 (33.3%)</p>	None

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
Patients ≥16 years of age admitted to the University Hospital of Liège with moderate-to-severe confirmed COVID-19	N	CG: did not receive the IG in each comparison (n=13 for IG1, 76 for IG2, 3for IG3, 77 for IG4) Total: 101 analyzed/199 enrolled	IG4 vs. CG4: 18/24 (75%) vs. 53/77 (68.8%) None	
ROB: High				
Milne, 2021 UK Prospective cohort April to August 2020 Patients ≥18 years of age admitted to a single UK hospital with confirmed COVID-19 pneumonia, with an oxygen requirement during their admission ROB: Some concerns	Hospitalized (11% ICU admission) Median 60.0 (IQR: 53-72 in IG, 51-68 in CG); 31%; NR Moderate-to-severe N	IG: Dexamethasone (orally 6mg/day for up to 10 days or duration of hospitalization, received following the pre-print of the RECOVERY trial [June 2020], or as part of randomisation to that trial), during hospitalization (n=39) CG: No dexamethasone (n=48) Total: 87 analyzed/198 recruited	Prevalence of ongoing symptoms (total # and as a rate from a list 17 symptoms), 8 months post-admission IG: 16/39 (41.0%) CG: 12/48 (25.0%) IG: n=73 symptoms, 1.9 symptoms/patient (n per group not reported) CG: n=152 symptoms, 3.2 symptoms/patient (n per group not reported) P=0.01 None	Fatigue (single item) Psychopathology (MCS from SF-36; range 0-100, higher score=less mental disability)
Berentschot, 2024 Netherlands Retrospective cohort	Hospitalized (40% ICU admission) Median 60.0 (IQR: 53-68); 30.3%; 1.2%	IG1: Steroids only (n=211) IG2: Anti-inflammatory treatment (n=47) IG3: Antivirals (n=62)	Non-recovery status based on self-reported recovery assessed with the COVID-19 Core Outcome Measure for recovery (dichotomized into completely recovered and not completely recovered [comprising mostly recovered, somewhat recovered, half recovered, and not recovered at all]), median 730.0 (IQR: 726.0-739.0) days post-discharge	Fatigue (FAS score, range: 10-50, higher score=more fatigue)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
<p>July 2020 to October 2021</p> <p>Patients ≥18 years of age hospitalized for COVID-19 and within 6 months post-discharge. Included patients who had completed at least one of our outcomes of interest at the 2-year follow-up</p> <p>ROB: High</p>	<p>Moderate-to-severe</p> <p>N</p>	<p>All during hospitalization</p> <p>CG: No steroids, anti-inflammatory treatment, or antivirals, may have received (hydroxy)chloroquine (n=102)</p> <p>Total: 502 analyzed/502 enrolled (N eligible NR)</p>	<p>IG1: 144/211 (68.2%)</p> <p>IG2: 37/47 (78.7%)</p> <p>IG3: 47/62 (75.8%)</p> <p>CG: 78/102 (76.5%)</p> <p>Between-groups adjusted P=0.23</p>	<p>Breathlessness/Dyspnea (dyspnea, mMRC score ≥1; 6-MWT)</p> <p>Cognitive failure (CFQ score; range 0-100, higher score=more cognitive failure)</p> <p>HRQoL (EQ-5D-5L index; range 0-1, higher score=higher quality of life)</p>
<p>Greenstein, 2024</p> <p>US and Spain</p> <p>Open-label RCT</p> <p>NR</p> <p>Patients admitted to one of 34 hospitals in the US and Spain for COVID-19 (noncritically ill patients who were not receiving ICU-level care at enrollment) and were expected to be hospitalized for ≥72 hours</p>	<p>Hospitalized (0.0% ICU)</p> <p>Mean 61.0; NR; NR</p> <p>Noncritically ill (i.e., absence of critical care-level organ support at enrollment)</p> <p>N</p>	<p>IG: Therapeutic-dose heparin for up to 14 days or until recovery/discharge (n=289) vs. CG: usual care with prophylactic-dose heparin (n=282)</p> <p>IG2: Antiplatelet (aspirin or others) agents (n=163)</p> <p>IG3: Anticoagulant therapies (n=447)</p> <p>IG4: Steroids (N=462)</p> <p>IG5: Remdesivir (N=381)</p> <p>All during hospitalization</p>	<p>Self-reported presence of any symptom (from a list of 6 symptoms), at 3 months post-enrollment</p> <p>IG1: 153/ 289 (53%)</p> <p>CG: 135/282 (47.9%)</p> <p>aOR: 1.19 (95% CI: 0.85, 1.66), P=0.30</p> <p>IG2: 80/163 (49%)</p> <p>IG3: 221/447 (49.4%)</p>	<p>Fatigue (single item)</p> <p>Breathlessness/Dyspnea (average of shortness of breath at rest and shortness of breath with exertion, single items)</p> <p>Cognitive impairment (single item)</p> <p>Psychopathology (EQ-5D-5L subscore, moderate to extreme anxiety/depression)</p> <p>HRQoL (EQ-5DL index; range 0-100, higher)</p>

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: High		Total: 571 analyzed/727 randomized	IG4: 235/462 (50.9%) IG5: 191/381 (50.1%) None	score=higher quality of life; EQ-VAS)
Boglione 2022 Italy Retrospective cohort March 2020 to January 2021 Patients affected by COVID-19 and hospitalized at Saint Andrea Hospital, and followed in a 'post-COVID ambulatory' care for at least 6 months after discharge ROB: Some concerns	Hospitalized (13.8% ICU admitted) Median 65.0 (IQR: 56- 75.5); 22%; NR N	IG1: remdesivir (n=163), < 10 days of symptom onset IG2: corticosteroids (n=390), timing NR CG: no remdesivir (n=286) for IG1, no corticosteroids (n=59) for IG2 (could have received other medications) Total: 435 analyzed/449 enrolled	The level of functional status and the PCC severity reported using the PCFS which assigns the presence of significant long COVID for values >2. Grades 3–4 were referred to significant limitations in everyday life with important functional limitations Crude proportion NR aOR, IG1 vs. CG: 0.641 (0.413, 0.782); P<0.001 aOR, IG2 vs. CG: 2.2 (0.55, 4.9); P-value NR None	None
Cardona-Pascual, 2023 Spain Retrospective matched cohort	Hospitalized (17% ICU admission) Mean 58.9 (SD: 13.2); 36.5%; NR	IG: Tocilizumab, either with 600mg (400mg for weight<75kg) followed by a second dose of 400mg 12h apart, or a unique dose of 600mg (400mg for weight<75kg); during acute infection (n=129)	Patient/clinic reported persistent COVID-19 symptoms (≥ 1 symptom, not present prior to infection), 6 months after discharge	Breathlessness/Dyspnea (breathless/dyspnea, single item)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
<p>March to April 2020</p> <p>Discharged SARS-CoV-2 patients from Valid' Hebron Barcelona Campus Hospital after surviving the first wave in 2020. All patients had to meet the criteria for tocilizumab therapy in accordance with the Spanish Agency of Medicines and Medical Devices</p> <p>ROB: Some concerns</p>	N	<p>CG: No tocilizumab, but eligible (n=262)</p> <p>All treated with standard pharmacological protocol, including antiviral drugs (lopinavir plus ritonavir twice a day), hydroxychloroquine 400mg/day and antibiotic prophylaxis (azithromycin and ceftriaxone).</p> <p>Total: 392 analyzed/405 enrolled</p>	<p>IG: 47/129 (36.5%)</p> <p>CG: 82/269 (31.3%)</p> <p>Propensity score matching aOR: 1.02 (0.62, 1.68)</p> <p>None</p>	<p>Psychopathology (anxiety/depression, single item)</p> <p>Cognitive impairment (single item)</p>
<p>Davelaar, 2023</p> <p>The Netherlands</p> <p>Retrospective cohort</p> <p>March 2020 to September 2021</p> <p>Adult patients (≥18 years old) who were hospitalized due to COVID-19 symptoms confirmed using a PCR test</p>	<p>Hospitalized (% ICU NR)</p> <p>Mean 62.1 (SD: 9.5); 38.2%; NR</p> <p>31% "High" severity admission</p> <p>N</p>	<p>IG1: Antibiotics, as prophylaxis or on suspicion of a bacterial infection, ceftriaxone 2000 mg was primarily used (n=89)</p> <p>IG2: Anticoagulants (dalteparin), standard for most in acute phase (n=100)</p> <p>IG3: Corticosteroids (mostly dexamethasone), if indicated (n=73)</p> <p>IG1+IG2 (n=71)</p> <p>IG1+IG3 (n=53)</p> <p>IG2+IG3 (n=64)</p>	<p>Self-report using multiple questions requiring limitations in health, worse health than previous year, interference with daily life, and at least one of mental health, fatigue, or dyspnea symptoms, 6 months after discharge</p> <p>IG1 vs. CG1: 24/89 (27.0%) vs. 9/34 (26.5%)</p> <p>a OR: 1.26 (0.47, 3.39)</p> <p>IG2 vs. CG2: 25/100 (25.0%) vs. 8/23 (34.8%) aOR: 0.55 (0.18, 1.71)</p> <p>IG3 vs. CG3: 16/73 (21.9%) vs. 17/50 (34.0%) aOR: 0.32 (0.11, 0.90)</p>	None

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: Some concerns		IG1+IG2+IG3 (n=46) Variable doses and durations, per protocol; during acute phase CG: did not receive the IG in each comparison (n= 34 for IG1, 23 for IG2, 50 for IG3, 52 for IG1+IG2, 70 for IG1+IG3, 59 for IG2+IG3, 77 for IG1+IG2+IG3) Total: 123 analyzed/123 enrolled	IG1+IG2 vs CG: 18/71 (25.4%) vs. 15/52 (28.8%) aOR: 0.81 (0.35, 2.27) IG1+IG3 vs. CG: 13/53 (24.5%) vs. 20/70 (28.6%) aOR: 0.79 (0.31, 1.99) IG2+IG3 vs. CG: 13/64 (20.3%) vs. 20/59 (33.9%) aOR: 0.34 (0.12, 0.93) IG1+IG2+IG3 vs. CG: 11/46 (23.9%) vs. 22/77(28.6%) aOR: 0.78 (0.29, 2.06) None	
Leavy, 2023 (PHOSP study) UK Retrospective matched cohort February 2020 to March 2021 (discharge dates) Adults admitted to hospital for COVID-19 and meeting current guideline recommendations for dexamethasone treatment; not on immunosuppressants	Hospitalized (% ICU NR) Mean 58.6 (SD: 12.2); 35.4%; NR Moderate-to-critical (all COVID-19 requiring at least oxygen supplementation; 18% severe) N	IG: Corticosteroids (any systemic, oral or intravenous), during their hospital admission (n=738) CG: No corticosteroid (n=489) Total: 1,227 analyzed/1,888 enrolled	Presence of any symptoms at 1 year after discharge (long list of symptoms) IG: 657/738 (89.1%) CG: 424/489 (86.6%) P=0.508 None	Fatigue (FACIT fatigue score ; range 0-52, higher score=less fatigue ; Fatigue VAS score) Breathlessness/Dyspnea (airway obstruction, FEV1/FVC <0.7; FEV1 % predicted <80%; FVC % predicted <80%; breathlessness VAS score, dyspnea-12 score) Cognitive impairments (mild cognitive

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: High				impairment or worse, MoCA score <12) Psychopathology (probably general anxiety disorder, GAD score >8; PCL-5 score, PHQ-8 score) HRQoL (EQ-5D-5L; range 0-1, higher score=higher quality of life)
Evans, 2021 (PHOSP study) UK Retrospective cohort March 5 to November 30, 2020 (discharge dates) Patients ≥18 years old discharged from one of 53 National Health Service hospitals after admission for confirmed or clinician diagnosed COVID-19 (patients required to attend a research visit 2-7 months post discharge)	Hospitalized (% ICU NR) Mean 58.0 (SD: 13.0); 36%; NR 17% very severe, 21% severe, 17% moderate, 46% mild N	IG1: Systemic steroids, oral or intravenous, during hospitalization (n=301) IG2: Antibiotics, during hospitalization (n=841) IG3: Therapeutic dose anticoagulants, during hospitalization (n=321) CG: did not receive the IG in each comparison (n=776 for IG1, 236 for IG2, 756 for IG3) Total: 830 analyzed/1,170 enrolled	Patient-perceived recovery (i.e., fully recovered from COVID-19), median of 5·9 months (IQR 4·9–6·5) after discharge Crude proportions NR IG1 vs. CG, aOR: 1.02 (0.70, 1.49), P=0.909 IG2 vs. CG, aOR: 1.21 (0.77, 1.90), P=0.410 IG3 vs. CG, aOR: 0.78 (0.53, 1.15), P=0.202 None	None

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
ROB: High				
Ko, 2022 France Retrospective cohort February to December 2020 (discharge dates) Hospitalized adult patients with COVID-19, who were discharged from the Amiens Picardie University Hospital, France and had face-to-face assessment 4 months after admission ROB: Some concerns	Hospitalized (37% ICU admission) Mean 65.0 (SD: 14.0); 42%; NR N	IG1: Corticosteroids, 6mg (n=104) IG2: Antivirals (lopinavir/ritonavir/remdesivir (n=61) IG3: Hydroxychloroquine (n=45) All administered based on clinical decisions and during hospitalization CG: did not receive the IG in each comparison 9n=202 for IG1, 245 for IG2, 261 for IG3) Total: 306 analyzed/454 eligible for follow-up	Self-reported at least one current symptom, 4 months after admission IG1 vs. CG: 66/104 (63.5%) vs. 127/202 (62.8%) aOR: 1.06 (0.60, 1.88), P=0.84 (accounting for other treatments received) IG2 and IG3: did not have any effect on prolonged symptoms (data NR) Subgroups: ICU subpopulation, patients with non-invasive ventilation, and those receiving mechanical ventilation	Breathlessness/Dyspnea (dyspnea, single item)
Nevalainen, 2022 Finland Open-label RCT July 2020 to January 2021 Adults ≥18 years old with a PCR- confirmed	Hospitalized (11% ICU admission) Mean 58.3 (SD: 13.4); 36%; NR 73% received dexamethasone	IG: Intravenous remdesivir once daily until discharge or a maximum of 10 days, 89% ≤2 days after hospitalization (n=98 analyzed/114 randomized) CG: No remdesivir (n=83 analyzed/94 randomized)	Recovery from COVID-19 (fully or largely), 1 year after discharge IG: 83/98 (85%) CG: 71/83 (86%) Unadjusted RR: 0.94 (0.47, 1.90)	Fatigue (moderate/severe, single item) Breathlessness/Dyspnea (exertional dyspnea, mmRC score 2-4) Cognitive impairments (average of moderate/severe problems with memory)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
<p>diagnosis of COVID-19 requiring hospitalization for more than 24 hours (from 11 hospitals in Finland), restricted to those who completed the 1-year follow-up</p> <p>ROB: Some concerns</p>	N	Total: 181 analyzed/208 randomized	Subgroup: need of oxygen therapy during hospital admission	<p>and attention/concentration, single items)</p> <p>Psychopathology (EQ-5D-5L subscore, moderate to extreme anxiety/depression; depression; mental anxiety)</p> <p>HRQoL (EQ-VAS; range 0-100, higher score=higher quality of life)</p> <p>Return to work (unable to return to work or study, single item)</p>
<p>Xu, 2023</p> <p>China</p> <p>Non-randomized clinical controlled trial</p> <p>November 5 to 28, 2022</p> <p>Adults aged between 18-50 years old, infected with the Omicron variant who</p>	<p>Hospitalized (% ICU NR)</p> <p>Mean 29.3 (SD: 7.34); 40%; NR</p> <p>Mild-to-moderate</p> <p>N</p>	<p>IG: Paxlovid (oral nirmatrelvir plus ritonavir) twice daily for 5 days, ≤5 days of symptom onset (n=172 analyzed/195 completed the IG) (most not at high-risk)</p> <p>CG: No exposure, but eligible. Received standard treatment (n=95 analyzed/120 enrolled)</p> <p>Total: 267 analyzed/320 enrolled</p>	<p>Self-report PCC symptoms (WHO criteria), at/within 3 months post-discharge</p> <p>IG: 32/172 (18.6%)</p> <p>CG: 30/95 (31.6%)</p> <p>P=0.016</p> <p>aOR: 0.531 (0.290, 0.974), P=0.041</p>	<p>Fatigue (single item)</p> <p>Any adverse event (self-reported)</p> <p>Serious adverse events (self-reported)</p>

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
were admitted to the designated hospital for treating COVID-19 in Shijiazhuang ROB: High				
Wang 2023 China Prospective comparative cohort using retrospective exposure data April to June 2022 (discharge dates) High-risk patients who were discharged from Shidong Hospital and who completed the follow-up ROB: IG1: Some concerns; IG2+IG3: High	Hospitalized (% ICU NR) Mean 74.1 (SD: 11.4); 54.4%; NR Moderate-to-critical N	IG1: Paxlovid (nirmatrelvir plus ritonavir), timing NR (n=178) IG2: Glucocorticoids (n=21) IG3: Antibiotics (n=157) CG: did not receive the IG in each comparison (n=456 for IG1, 613 for IG2, 477 for IG3) Total: 634 analyzed/747 eligible for follow-up	Self-reported symptom checklist (13 items), 6 months after discharge Crude proportions NR IG1 vs. CG: aOR (age and COPD): 0.349 (0.205, 0.595), P<0.001 IG2 vs. CG: unadjusted OR: 1.377 (0.524, 3.616), P=0.516 IG3 vs CG: unadjusted OR: 1.904 (1.271, 2.853), P=0.002 None	None
Frontera, 2021 US	Hospitalized (32.2% ICU admission) Median 68.0 (IQR: 55-77) in neurological cases and	IG1: Corticosteroid (n=101) IG2: Hydroxychloroquine (n=272)	Functional incapacity (i.e., Barthel index <100), median of 6.7 (IQR: 6.5-6.8) months post-neurological symptom onset	Fatigue (worse than average, neuro-QoL subscore, t-score >50)

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
<p>Retrospective matched cohort</p> <p>March 10 to May 20, 2020</p> <p>Patients ≥18 years of age hospitalized at four New York hospitals and discharged alive; propensity-matched those with and without new neurological complications during index hospitalization</p> <p>ROB: High</p>	<p>69.0 (IQR: 57-78) in controls; 35%; NR</p> <p>N</p>	<p>IG3: Azithromycin (n=246)</p> <p>IG4: Therapeutic anticoagulation (n=134)</p> <p>IG5: Zing (n=NR)</p> <p>All during hospitalization</p> <p>CG: did not receive the IG in each comparison (n=281 for IG1, 110 for IG2, 136 for IG3, 248 for IG4, NR for IG5)</p> <p>Total: 382 (n=196 and 186 with and without neurological complications, respectively) analyzed/700 eligible for follow-up</p>	<p>Crude proportions: NR</p> <p>IG1 vs. CG, unadjusted OR 0.48 (0.29, 0.80), P=0.005</p> <p>Unadjusted P-values:</p> <p>IG2 vs. CG=0.970</p> <p>IG3 vs. CG=0.078</p> <p>IG4 vs. CG=0.078</p> <p>IG5 vs. CG=0.407</p> <p>None</p>	<p>Cognitive impairment (moderate or worse, telephone MOCA score <18)</p> <p>Psychopathology (worse than average anxiety and depression, neuro-QoL subscore, t-score >50)</p> <p>Return to work (not returned to work of those working pre-morbidly, single item)</p>

First Author, Year; Country; Study Design ¹ ; Timing of Infection Recruitment setting and participant eligibility Risk of bias for primary outcome	Type of Acute Care Average age (years); % Female; % Vaccinated COVID-19 Illness Severity Eligible Population All Having Post-acute Symptoms (Y/N)	Intervention/Exposure Group (IG): Description & Timing Control Group (CG) N analyzed/enrolled	PCC Outcome Description & Timing Main Results Available Sub-group Data	Reported findings related to secondary outcomes (bold indicates data used for synthesis where >1)
Meije, 2021 Spain Prospective cohort March to May 2020 (discharge date) Patients >15 years of age who were discharged after hospitalization for COVID-19 ROB: High	Hospitalized (8.9% ICU admission) Mean 68.8 (SD: 12.7); 43% female Variable severity (oxygen supplementation 74.8%; 1% IV)	IG: Outpatient assessment (standard follow-up protocol checklist of symptoms and adverse events, medical history, physical examination, laboratory testing including chest x-ray) with referrals as required (n=294) CG: None Total: 302/461	Proportion with any persistent symptoms, median 7 (range 6-7.4) months after hospital discharge At post discharge assessment vs. 7-month follow-up: 228/294 (77.6%) vs. 147/294 (50.0%)	Breathlessness/Dyspnea (dyspnea, single item) Psychopathology (need for psychological medication, single item)

Abbreviations: aOR: adjusted odds ratio; aHR: adjusted hazard ratio; CFQ: Cognitive Failures Questionnaire; CG: control group; EQ-5D: EuroQol-5 Dimensions-5 Levels; HRQoL: health-related quality of life; IG: intervention group; IQR: inter-quartile range; MCS: mental component score; mMRC: Modified Medical Research Council; NR: not reported; PCR- Polymerase Chain Reaction; SD: standard deviation; SF-36: 36-Item Short Form Health Survey questionnaire; VS: versus

¹Study design: focus was on whether the exposure and baseline demographic information was prospectively or retrospectively collected.

Table S2. Quality assessment of the included cohort studies

Author, year Outcome	1. Were the two groups similar and recruited from the same population?	2. Were the exposures measured similarly to assign people to both exposed and unexposed groups?	3. Was the exposure measured in a valid and reliable way?	4. Were confounding factors identified?	5. Were strategies to deal with confounding factors stated?	6. Were the groups/ participants free of the outcome at the start of the study (or at the moment of exposure)?	7. Were the outcomes measured in a valid and reliable way?	8. Was the follow up time reported and sufficient to be long enough for outcomes to occur?	9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored?	10. Were strategies to address incomplete follow up utilized?	11. Was appropriate statistical analysis used ?	Covid test valid?	Evidence of selective reporting of results and/or analyses?	Evidence of missing outcome data?	Overall rating
Rocha, 2023 PCC: Long COVID	+	+	-	+	-	+	+	+	?	-	-	+	+	-	High
Rocha, 2023 Fatigue	+	+	?	+	-	+	?	+	?	-	-	+	+	-	High
Rocha, 2023 Dyspnea	+	+	?	+	-	+	?	+	?	-	-	+	+	-	High
Rocha, 2023 Memory loss	+	+	?	+	-	+	?	+	?	-	-	+	+	-	High
Rocha, 2023 Attention loss	+	+	?	+	-	+	?	+	?	-	-	+	+	-	High
Patel, 2024 PCC: PASC	?	+	+	+	+	+	+	+	?	-	?	+	+	-	Some concerns
Patel, 2024 Anxiety/mood disorder	?	+	+	+	+	+	?	+	?	-	?	+	+	-	Some concerns
Durstenfeld, 2023	+	+	-	+	+	+	+	+	-	?	?	+	-	-	High

PCC: Long COVID symptoms																	
Cardona-Pascual, 2023	+	+	+	+	+	+	?	+	+	NA	+	+	?	-	Some concerns		
PCC: Persisting symptoms																	
Cardona-Pascual, 2023	+	+	+	+	-	+	?	+	+	NA	?	+	?	-	High		
Breathlessness/dyspnea																	
Cardona-Pascual, 2023	+	+	+	+	-	+	?	+	+	NA	?	+	?	-	High		
Depression/anxiety																	
Cardona-Pascual, 2023	+	+	+	+	-	+	?	+	+	NA	?	+	?	-	High		
Cognitive impairment																	
Davelaar, 2023	+	+	+	+	+	?	?	+	+	NA	+	+	-	-	Some concerns		
PCC: Post-COVID syndrome																	
Bertuccio, 2023	+	+	+	+	+	+	?	+	-	-	?	+	-	-	High		
PCC: Long COVID symptoms																	
Congdon, 2023	+	+	?	+	+	+	+	+	?	-	?	+	-	-	Some concerns		

PCC: Long COVID symptoms																	
Congdon, 2023 Dyspnea	+	+	?	+	-	+	?	+	?	-	-	+	-	-	-	High	
Congdon, 2023 Generalized fatigue	+	+	?	+	-	+	?	+	?	-	-	+	-	-	-	High	
Congdon, 2023 Brain fog	+	+	?	+	-	+	?	+	?	-	-	+	-	-	-	High	
Chuang, 2023 PCC: Post-acute COVID-19 symptoms	+	+	+	+	+	+	+	+	+	NA	+	+	-	-	-	Low	
Chuang, 2023 Hospitalization	+	+	+	+	+	+	+	+	+	NA	+	+	-	-	-	Low	
Chuang, 2023 Fatigue	+	+	+	+	+	+	+	+	+	NA	+	+	-	-	-	Low	
Chuang, 2023 Cognitive impairments	+	+	+	+	+	+	+	+	+	NA	+	+	-	-	-	Low	
Leavy, 2023 PCC: Any symptoms	+	+	-	+	+	+	+	+	?	-	?	?	-	-	-	High	
Leavy, 2023 Recovery: Fully recovered from COVID-19	+	+	-	+	+	+	?	+	?	-	?	?	-	-	-	High	

Leavy, 2023 HRQoL	+	+	-	+	+	+	?	+	?	-	?	?	-	-	High
Leavy, 2023 Fatigue	+	+	-	+	+	?	+	+	?	-	?	?	-	-	High
Leavy, 2023 Anxiety	+	+	-	+	+	?	+	+	?	-	?	?	-	-	High
Leavy, 2023 Cognitive impairment	+	+	-	+	+	?	+	+	?	-	?	?	-	-	High
Leavy, 2023 Lung function	+	+	-	+	+	?	+	+	?	-	?	?	-	-	High
Evans, 2021 Recovery: Patient-perceived recovery	+	+	+	+	+	+	?	+	-	-	?	+	-	-	High
Darcis, 2021 PCC: At least one symptom	?	+	?	+	-	+	?	+	-	-	?	-	-	-	High
Milne, 2021 PCC: Ongoing symptoms	+	+	+	+	?	+	?	+	+	NA	?	+	-	-	Some concerns
Milne, 2021 Fatigue	+	+	+	+	?	+	?	+	+	NA	?	+	-	-	Some concerns
Milne, 2021	+	+	+	+	?	?	+	+	+	NA	?	+	-	-	Some concerns

Mental component score																	
Berentschot, 2024 Recovery: Completely recovered	?	+	+	+	-	+	+	+	?	-	-	+	+	-		High	
Berentschot, 2024 Dyspnea	?	+	+	+	-	?	+	+	?	-	-	+	+	-		High	
Berentschot, 2024 Fatigue	?	+	+	+	-	?	+	+	?	-	-	+	+	-		High	
Berentschot, 2024 Cognitive failures	?	+	+	+	-	?	+	+	?	-	-	+	+	-		High	
Berentschot, 2024 HRQoL	?	+	+	+	-	?	+	+	?	-	-	+	+	-		High	
Boglione, 2024 PCC: Long post-COVID syndrome	?	+	?	+	+	+	+	+	+	NA	+	?	-	-		Some concerns	
Ko, 2022 PCC: Persistent symptoms	+	+	+	+	+	+	?	+	?	-	?	+	?	-		Some concerns	
Ko, 2022 Dyspnea	+	+	+	+	+	+	?	+	?	-	?	+	?	-		Some concerns	

Wang, 2023 PCC: Long COVID (comparison 1)	?	+	+	+	?	+	+	+	+	NA	?	?	-	-	Some concerns
Wang, 2023 PCC: Long COVID (comparison 2)	?	+	+	+	-	+	+	+	+	NA	?	?	-	-	High
Wang, 2023 PCC: Long COVID (comparison 3)	?	+	+	+	-	+	+	+	+	NA	?	?	-	-	High
Frontera, 2021 PCC: Functional incapacity	?	+	+	+	-	?	+	+	?	-	-	+	-	+	High
Frontera, 2021 Cognitive impairment	?	+	+	+	-	?	+	+	?	-	-	+	-	+	High
Frontera, 2021 Anxiety	?	+	+	+	-	?	+	+	?	-	-	+	-	+	High
Frontera, 2021 Depression	?	+	+	+	-	?	+	+	?	-	-	+	-	+	High
Frontera, 2021 Fatigue	?	+	+	+	-	?	+	+	?	-	-	+	-	+	High
Frontera, 2021 Return to work	?	+	+	+	-	+	?	+	?	-	-	+	-	+	High
Meije, 2021	+	+	+	+	-	+	?	+	-	+	-	+	-	-	High

PCC: Persistent symptoms																
Meije, 2021 Need for psychological medication	+	+	+	+	-	+	-	+	-	+	-	+	-	-	-	High
Meije, 2021 Dyspnea	+	+	+	+	-	+	-	+	-	+	-	+	-	-	-	High

+: Yes/low risk of bias; -: No/high risk of bias; ?: Unclear/Some concerns of bias; NA: Not applicable

Table S3: Quality assessment of the included randomized trials

Author, year	Domain 1. Randomization process	Domain 2. Deviations from the intended interventions (effect of assignment to intervention)	Domain 3. Missing outcome data	Domain 4. Measurement of the outcome	Domain 5. Selection of reported results	COVID-19 test valid?	Overall rating
Greenstein, 2024 PCC: Presence of any symptoms	+	?	-	?	+	+	High
Greenstein, 2024 HRQoL	+	?	-	?	+	+	High
Greenstein, 2024 Anxiety/depression	+	?	-	?	+	+	High
Greenstein, 2024 Shortness of breath with exertion	+	?	-	?	+	+	High

Greenstein, 2024	+	?	-	?	+	+	High
Shortness of breath at rest							
Greenstein, 2024	+	?	-	?	+	+	High
Cognitive impairment							
Greenstein, 2024	+	?	-	?	+	+	High
Fatigue							
Kolesnyk, 2024	+	+	+	+	+	+	Low
PCC: Post-COVID functional scale							
Kolesnyk, 2024	+	+	+	+	+	+	Low
Attention deficit							
Kolesnyk, 2024	+	+	+	+	+	+	Low
Fatigue							
Kolesnyk, 2024	+	+	+	+	+	+	Low
Depression							
Kolesnyk, 2024	+	+	+	+	+	+	Low
Anxiety							
Kolesnyk, 2024	+	+	+	+	+	+	Low
Withdrawals due to AEs							
Gebo, 2023	+	+	+	+	+	?	Low
PCC: Any new symptom							
Gebo, 2023	?	+	+	+	+	?	Some concerns
Subgroup by timing of drug administration, PCC: Any new symptom							

Xu, 2023	-	?	?	?	+	+	High
PCC: Post COVID condition							
Xu, 2023	-	?	?	?	+	+	High
Fatigue							
Xu, 2023	-	?	+	?	+	+	High
Adverse events							
Bramante, 2023	+	+	?	+	+	+	Some concerns
PCC: Long COVID							
Bramante, 2023	+	+	+	?	+	+	Low
Serious AEs							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
Recovery							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
HRQoL							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
Fatigue							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
Anxiety/depression							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
Dyspnea							
Nevalainen, 2022	+	?	+	?	+	+	Some concerns
Problems with attention and concentration							

Nevalainen, 2022 Memory difficulties and forgetting things	+	?	+	?	+	+	Some concerns
Nevalainen, 2022 Post-exertional malaise	+	?	+	?	+	+	Some concerns
Nevalainen, 2022 Inability to return to work	+	?	+	?	+	+	Some concerns

+: Low risk of bias; -: High risk of bias; ?: Unclear/Some concerns of bias; NA: Not applicable

Table S4. Summary of findings for secondary outcomes, by intervention

Study design, acute care setting (Number of studies; Sample size)	Pooled estimate (95% CI); I ²	GRADE rating ¹	What happens?
Fatigue: Antivirals			
Trials, inpatients (1 study; N=181)	Remdesivir: Inpatients, RR (95% CI): 0.88 (95% CI: 0.54, 1.44)	Very low ^{d, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of moderate to severe fatigue.

Observational, inpatients (1 study; N=267)	Inpatients, OR (95% CI): 0.57 (0.25-1.29) Inpatients, MD (95% CI): 1.50 (-1.08-4.08)	Very low ^G	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of antivirals on the risk of fatigue.
Observational, inpatients, continuous (1 study [Berentschot 2024], n=197)			
Observational, outpatients (2 studies; N=24,990)	Paxlovid (nirmatrelvir and ritonavir): Outpatient pooled estimate RR (95% CI): 0.91 (0.79-1.05); I² = 0%	Low	Among individuals who received outpatient COVID-19 care, paxlovid (nirmatrelvir and ritonavir) may not reduce the risk of fatigue.
Fatigue: Hydroxychloroquine			
Observational, inpatients (1 study; N=382)	Inpatients, p=0.221	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of hydroxychloroquine on the risk of worse than average fatigue.
Fatigue: Steroids			
Observational, inpatients (2 studies; N=469)	Inpatient pooled estimate OR (95% CI): 1.05 (0.23-4.85); I² = 89%	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of steroids on the risk of fatigue.
Observational, inpatients continuous (2 studies [Berentschot 2024; Leavy 2023]; N=1,594)	Inpatient pooled estimate SMD (95% CI): 0.02 (-0.09-0.12); I² = 0%		
Fatigue: Anti-inflammatory treatment			
Observational, inpatients (1 study [Berentschot 2024]; N=176)	Inpatients, MD (95% CI): 0.10 (-2.77-2.97)	Very low ^{a, d}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of anti-inflammatory treatment on the risk of fatigue.
Fatigue: Azithromycin			
Observational, inpatients (1 study; N=382)	Inpatients, p=0.633	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of azithromycin on the risk of worse than average fatigue.
Fatigue: Therapeutic anticoagulants			

Trials, inpatients (1 study; N=571)	Therapeutic-dose heparin (vs. prophylactic-dose heparin): Inpatients, RR (95% CI): 1.05 (0.85-1.30)	Low ^{a, g}	Among individuals who received inpatient COVID-19 care, therapeutic-heparin versus prophylactic-dose heparin may not reduce the risk of fatigue.
Observational, inpatients (1 study; N=382)	Inpatients, OR (95% CI): 1.80 (1.10-3.10); p=0.022	Very low ^{a, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic anticoagulants on the risk of worse than average fatigue.
Fatigue: Probiotics			
Trials, outpatients (1 study; N=69)	Inpatients, RR (95% CI): 1.34 (0.68-2.63)	Very low ^{e, g}	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of probiotics on the risk of fatigue.
Fatigue: Zinc			
Observational, inpatients (1 study; N=NR)	Inpatients, p=0.272	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of zinc on the risk of worse than average fatigue.
Fatigue: Activity			
Observational, outpatients (1 study; N=823)	Remained active (vs. became inactive): Outpatients, RR (95% CI): 0.36 (0.25-0.52)	Very low ^a	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of activity level on the risk of fatigue.
Breathlessness/Dyspnea: Antivirals			
Trials, inpatients (1 study; N=181)	Remdesivir: Inpatients, RR (95% CI): 0.61 (0.20, 1.85)	Very low ^{d, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of exertional dyspnea.
Observational, inpatients (1 study; N=186)	Inpatients, RR (95% CI): 1.16 (0.84-1.60)	Very low ^{a, d, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of antivirals on the risk of breathlessness/dyspnea.
Observational, outpatients (1 study; N=500)	Paxlovid (nirmatrelvir and ritonavir): Outpatients, RR (95% CI): 0.68 (0.42-1.09)	Very low ^{a, g}	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of paxlovid (nirmatrelvir and ritonavir) on the risk of breathlessness/dyspnea.
Breathlessness/Dyspnea: Steroids			
Observational, inpatients (3 studies; N=1,865)	Inpatient pooled estimate OR (95% CI): 0.79 (0.59-1.05); I² = 0%	Very low ^{a, d}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of steroids on the risk of breathlessness/dyspnea.

	Sensitivity analysis (excluding high ROB studies [2 studies; N=1,559], both also >6 months): 0.82 (0.48-1.40); I ² = NA		
Breathlessness/Dyspnea: Anti-inflammatory treatment			
Observational, inpatients (1 study; N=159)	Inpatients, RR (95% CI): 0.80 (0.50-1.27)	Very low ^{a, d, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of anti-inflammatory treatment on the risk of breathlessness/dyspnea.
Breathlessness/Dyspnea: Therapeutic-dose heparin			
Trials, inpatients (1 study; N=571)	Therapeutic-dose heparin (vs. prophylactic-dose heparin): Inpatients, average RR (95% CI): 0.96 (0.56-1.36)	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic-dose heparin versus prophylactic-dose heparin on the risk of breathlessness/dyspnea.
Breathlessness/Dyspnea: Tocilizumab			
Observational, inpatients (1 study; N=391)	Inpatients, RR (95% CI): 2.03 (1.37-3.00)	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of tocilizumab on the risk of breathlessness/dyspnea.
Breathlessness/Dyspnea: Activity			
Observational, outpatients (1 study; N=823)	Remained active (vs. became inactive): Outpatients, RR (95% CI): 0.34 (0.18-0.65)	Very low ^a	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of activity level on the risk of breathlessness/dyspnea.
Breathlessness/Dyspnea: Outpatient assessment and referrals			
Observational, inpatients (1 study; N=294)	Post-discharge outpatient care: 28 (9.5%)	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of outpatient assessment and referrals on the risk of breathlessness/dyspnea.
Cognitive impairment: Antivirals			
Trials, inpatients (1 study; N=181)	Remdesivir: Inpatients, average RR (95% CI): 1.15 (0.40-1.90)	Very low ^{d, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of moderate to severe cognitive impairment.
Observational, inpatients (1 study [Berentschot 2024]; n=197)	Inpatients, MD (95% CI): -0.40 (-5.56-4.76)	Very low ^{a, d, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of antivirals on the risk of cognitive impairment.

Observational, outpatients (2 studies; N=24,990)	Paxlovid (nirmatrelvir and ritonavir): Outpatients, pooled estimate RR (95% CI): 0.72 (0.59-0.88); I² = 0%	Very low ^a	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of paxlovid (nirmatrelvir and ritonavir) on the risk of cognitive impairment.
Cognitive impairment: Hydroxychloroquine			
Observational, inpatients (1 study; N=382)	Inpatients, p=0.128	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of hydroxychloroquine on the risk of cognitive impairment.
Cognitive impairment: Steroids			
Observational, inpatients (1 study; N=965)	Inpatients, RR (95% CI): 0.84 (0.57-1.23)	Very low ^{a, d, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of steroids on the risk of cognitive impairment.
Observational, inpatients p-value (1 study, N=382)	Inpatients, p=0.982		
Observational, inpatients continuous (1 study [Berentschot 2024]; N=382); continuous	Inpatients, MD (95% CI): -1.60 (-5.68-2.48)		
Cognitive impairment: Anti-inflammatory treatment			
Observational, inpatients (1 study [Berentschot 2024]; N=176)	Inpatients, MD (95% CI): -2.50 (-6.28-1.28)	Very low ^{a, d, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of anti-inflammatory treatment on the risk of cognitive impairment.
Cognitive impairment: Tocilizumab			
Observational, inpatients (1 study; N=391)	IG: NR vs. CG: 1 (0.4%)	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of tocilizumab on the risk of cognitive impairment.
Cognitive impairment: Azithromycin			
Observational, inpatients (1 study; N=382)	Inpatients, p=0.188	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of azithromycin on the risk of cognitive impairment.
Cognitive impairment: Therapeutic anticoagulants			

Trials, inpatients (1 study; N=571)	Therapeutic-dose heparin (vs. prophylactic-dose heparin): Inpatients, RR (95% CI): 0.49 (0.22-1.07)	Low ^{a, g} (small-moderate difference) Very low ^{a, G} (large difference)	Among individuals who received outpatient COVID-19 care, therapeutic-dose heparin versus prophylactic-dose heparin may reduce the risk of cognitive impairment. Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic-dose heparin versus prophylactic-dose heparin on the risk of cognitive impairment.
Observational, inpatient (1 study; N=382)	Inpatients, p=0.995	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic anticoagulants on the risk of cognitive impairment.
Cognitive impairment: Zinc			
Observational, inpatients (1 study; N=NR)	Inpatients, p=0.523	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of zinc on the risk of cognitive impairment.
Cognitive impairment: Probiotics			
Trials, inpatients (1 study; N=69)	Inpatients, RR (95% CI): 1.44 (0.51-4.10)	Very low ^{e, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of probiotics on the risk of cognitive impairment.
Cognitive impairment: Activity			
Observational, outpatients (1 study; N=823)	Remained active (vs. became inactive): Outpatients, average RR (95% CI): 0.63 (0.40-0.86)	Very low ^{a, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of activity level on the risk of cognitive impairment.
Psychopathology: Antivirals			
Trials, inpatient (1 study; N=181)	Remdesivir: Inpatients, RR (95% CI): 1.27 (0.47-3.42)	Very low ^{d, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of moderate to severe anxiety.
Observational, outpatient (1 study; N=53,186)	Paxlovid (nirmatrelvir and ritonavir): Outpatients, RR (95% CI): 0.71 (0.69-0.74)	Low	Among individuals with risk factors for severe COVID-19 who received outpatient COVID-19 care, paxlovid (nirmatrelvir and ritonavir) may reduce the risk of psychopathology.
Psychopathology: Hydroxychloroquine			
Observational, inpatients (1 study; N=382)	Anxiety: Inpatients: p=0.945 Depression: Inpatients: p=0.500	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of hydroxychloroquine on the risk of psychopathology.

Psychopathology: Corticosteroids			
Observational, inpatients (1 study; N=1,227)	Anxiety: Inpatients, RR (95% CI): 0.96 (0.77-1.18)	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of corticosteroids on the risk of psychopathology.
Observational, inpatients p-values (1 study; N=382)	Anxiety: Inpatients: p=0.822 Depression: Inpatients: p=0.367		
Observational, inpatients, continuous (1 study; N=87)	Mental disability: MD (95% CI): -4.00 (-8.74-0.74)		
Psychopathology: Tocilizumab			
Observational, inpatients (1 study; N=391)	Inpatients, RR (95% CI): 0.90 (0.28-2.88)	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of tocilizumab on the risk of psychopathology.
Psychopathology: Azithromycin			
Observational, inpatients (1 study; N=382)	Anxiety: Inpatients: p=0.606 Depression: Inpatients: p=0.104	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of azithromycin on the risk of worse than average psychopathology.
Psychopathology: Therapeutic anticoagulants			
Trials, inpatients (1 study; N=410)	Therapeutic-dose heparin (vs. prophylactic-dose heparin): Inpatients, RR (95% CI): 1.06 (0.67-1.69)	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic-dose heparin versus prophylactic-dose heparin on the risk of moderate to extreme psychopathology.
Observational, inpatients (1 study; N=382)	Anxiety: Inpatients: p=0.914 Depression: Inpatients: p=0.982	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic anticoagulants on the risk of worse than average psychopathology.
Psychopathology: Zinc			
Observational, inpatients (1 study; N=NR)	Anxiety: Inpatients: p=0.906 Depression: Inpatients: p=0.621	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of zinc on the risk of worse than average psychopathology.
Psychopathology: Probiotics			

Trials, outpatients (1 study; N=69)	Inpatients, average RR (95% CI): 0.93 (0.00-2.98)	Very low ^{e, G}	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of probiotics on the risk of psychopathology.
Psychopathology: Outpatient assessment and referrals			
Observational, inpatients (1 study; N=294)	Post-discharge outpatient care: 30 (10.2%)	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of outpatient assessment and referrals on the risk of psychopathology (need for psychological medication).
Hospitalization: Paxlovid (Nirmatrelvir and ritonavir)			
Observational, outpatients (1 study; N=24,490)	Outpatients, RR (95% CI): 0.54 (0.45-0.65)	Low	Among individuals who received outpatient COVID-19 care, paxlovid (nirmatrelvir and ritonavir) may reduce the risk of psychopathology.
Health-related quality of life: Antivirals			
Trials, inpatients (1 study; N=181)	Remdesivir: Inpatients, OR (95% CI): 0.83 (0.49-1.40)	Low ^{d, g}	Among individuals who received inpatient COVID-19 care, remdesivir may not reduce the risk of worse health-related quality of life.
Observational, inpatients (1 study [Berentschot 2024]; N=197)	Inpatients, MD (95% CI): 0.01 (-0.06-0.08)	Very low ^{a, d}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of antivirals on the risk of worse health-related quality of life.
Health-related quality of life: Steroids			
Observational, inpatients (2 studies [Berentschot 2024; Leavy 2023]; N=1,594)	Inpatient pooled estimate MD (95% CI): -0.00 (-0.03-0.02); I² = 13%	Very low ^{a, d}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of steroids on the risk of worse health-related quality of life.
Health-related quality of life: Anti-inflammatory treatments			
Observational, inpatients (1 study; N=176)	Inpatients, MD (95% CI): 0.02 (-0.04-0.08)	Very low ^{a, d}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of anti-inflammatory treatments on the risk of worse health-related quality of life.
Health-related quality of life: Therapeutic-dose heparin			
Trials, inpatients (1 study [Greenstein 2024]; N=410)	Therapeutic-dose heparin (vs. prophylactic-dose heparin): Inpatients, MD (95% CI): 0.12 (-3.22-3.46)	Moderate ^a	Among individuals who received inpatient COVID-19 care, therapeutic-dose heparin versus prophylactic-dose heparin probably does not reduce the risk of worse health-related quality of life.
Post-exertional malaise: Remdesivir			

Trials, inpatients (1 study; N=181)	Inpatients, RR (95% CI): 0.41 (0.15-1.12)	Low ^{d, g} (small-moderate difference) Very low ^{d, G} (large difference)	Among individuals who received inpatient COVID-19 care, remdesivir may reduce the risk of moderate to severe prolonged general malaise following even light exertion. Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of moderate to severe prolonged general malaise following even light exertion.
Not returned to work or study: Remdesivir			
Trials, inpatients (1 study; N=111)	Inpatients, RR (95% CI): 0.26 (0.01-6.13)	Very low ^{d, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of remdesivir on the risk of not returning to work or study.
Not returned to work: Hydroxychloroquine			
Observational, inpatients (1 study; N=NR)	Return to work: Inpatients: p=0.192	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of hydroxychloroquine on the risk of not returning to work.
Not returned to work: Corticosteroids			
Observational, inpatients (1 study; N=NR)	Inpatients: OR (95% CI): 2.50 (1.25-5.00)	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of corticosteroids on the risk of not returning to work.
Not returned to work: Azithromycin			
Observational, inpatients (1 study; N=NR)	Return to work: Inpatients: p=0.458	Very low ^A	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of azithromycin on the risk of not returning to work.
Not returned to work: Therapeutic anticoagulants			
Observational, inpatients (1 study; N=NR)	Inpatients, OR (95% CI): 3.23 (1.67-6.25)	Very low ^a	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of therapeutic anticoagulants on the risk of not returning to work.
Not returned to work: Zinc			
Observational, inpatients (1 study; N=NR)	Inpatients, OR (95% CI): 0.43 (0.23-0.83)	Very low ^{a, g}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of zinc on the risk of not returning to work.
Any adverse events: Paxlovid (Nirmatrelvir and Ritonavir)			

Observational, inpatients (1 study; N=267)	Inpatients, RR (95% CI): 1.33 (0.48-3.65)	Very low ^{a, G}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of paxlovid (nirmatrelvir plus Ritonavir) on the risk of any adverse events.
Any adverse events: Probiotics			
Trials, outpatients (1 study; N=71)	Outpatients, RR (95% CI): 3.08 (0.13-73.23)	Very low ^{e, G}	Among individuals who received outpatient COVID-19 care, we are very uncertain about the effects of probiotics on the risk of any adverse events.
Serious adverse events: Paxlovid (Nirmatrelvir and Ritonavir)			
Observational, inpatients (1 study; N=267)	Inpatients: zero events	Very low ^{a, G, h}	Among individuals who received inpatient COVID-19 care, we are very uncertain about the effects of paxlovid (nirmatrelvir plus ritonavir) on the risk of serious adverse events.
Serious adverse events: Metformin			
Trials, outpatients (1 study; N=569)	Inpatients: zero events	Low ^{G, h}	Among individuals with a BMI of $\geq 25 \text{ kg/m}^2$ who received outpatient COVID-19 care, metformin may not reduce the risk of serious adverse events.
Serious adverse events: Fluvoxamine			
Trials, outpatients (1 study; N=319)	Inpatients: zero events	Low ^{G, h}	Among individuals with a BMI of $\geq 25 \text{ kg/m}^2$ who received outpatient COVID-19 care, fluvoxamine may not reduce the risk of serious adverse events.
Serious adverse events: Ivermectin			
Trials, outpatients (1 study; N=406)	Inpatients: zero events	Low ^{G, h}	Among individuals with a BMI of $\geq 25 \text{ kg/m}^2$ who received outpatient COVID-19 care, ivermectin may not reduce the risk of serious adverse events.
Serious adverse events: Metformin and Ivermectin			
Trials, outpatients (1 study; N=401)	Inpatients: zero events	Low ^{G, h}	Among individuals with a BMI of $\geq 25 \text{ kg/m}^2$ who received outpatient COVID-19 care, metformin and ivermectin may not reduce the risk of serious adverse events.
Serious adverse events: Metformin and Fluvoxamine			
Trials, outpatients (1 study; N=336)	Inpatients: zero events	Low ^{G, h}	Among individuals with a BMI of $\geq 25 \text{ kg/m}^2$ who received outpatient COVID-19 care, metformin and fluvoxamine may not reduce the risk of serious adverse events.

^aThresholds used in GRADE ratings were: RR 0.75-1.25 for little-to-no difference; RR 0.51-0.74 and 1.26-1.99 for a small-to-moderate difference, and ≤ 0.50 or ≥ 2.00 for a large difference.

Reasons (note use of capital letters when rating down twice under one domain for very serious concerns):

a=serious concerns of risk of bias; **b**=serious concerns of inconsistency; **c**=serious concerns of indirectness due to use of surrogate outcome; **d**=serious concerns of indirectness due to timing of outcome ascertainment (outcome ascertainment outside of 3 to 12-month follow-up); **e**=serious concerns of population (generalizability); **f**=serious concerns of outcome definition; **g**=serious concerns of imprecision. **h**=Some concerns about indirectness as serious adverse events were not defined (unclear whether requiring hospitalization), and serious concerns of imprecision due to zero events and sample size <2000.

Table S5. Subgroup data for post-COVID-19 condition

Author, Year	Intervention (s)	Subgroups/sensitivity analyses
Bertuccio, 2023	1. Monoclonal antibodies 2. Antivirals	<u>Sensitivity analysis by time period (most prevalent COVID variants):</u> Sensitivity analysis did not show any differences between the three periods, where prevalent variants were respectively Alpha, Delta and Omicron.
Chuang, 2023 (Patel 2024 used for primary outcome from TriNetX database)	Antivirals	<u>Subgroup, Age groups, OR (95% CI):</u> ≥65 years: 1.073 (0.967, 1.190) 45–64 years: 0.999 (0.898, 1.111) 18–44 years: 1.033 (0.904, 1.181) p-value: >0.05 <u>Subgroup, Sex, OR (95% CI):</u> Male: 1.042 (0.939, 1.155) Female: 1.004 (0.924, 1.092) p-value: >0.05 <u>Subgroup, Vaccination status, OR (95% CI):</u> Unvaccinated: 0.945 (0.869, 1.031) Vaccinated: 1.053 (0.951, 1.164) p-value: >0.05
Gebo, 2023	Convalescent plasma	<u>Subgroup, timing of intervention, RR (95% CI):</u> Convalescent plasma ≤5 days (vs. control plasma ≤5 days): Outpatients, RR: 0.84 (0.62-1.13) Convalescent plasma >5 days (vs. control plasma >5 days): Outpatients, RR: 1.00 (0.79-1.27)

Bramante, 2023	1. Metformin 2. Fluvoxamine 3. Ivermectin	<u>Subgroup, sex, HR (95% CI):</u> Female: Metformin vs. placebo: 0.56 (0.34-0.91) Male: Metformin vs. placebo: 0.76 (0.34-1.69) p-value: 0.53 Female: Fluvoxamine vs. placebo: 1.40 (0.74-2.65) Male: Fluvoxamine vs. placebo: 1.55 (0.52-4.62) p-value: 0.88 Female: Ivermectin vs. placebo: 1.04 (0.58-1.88) Male: Ivermectin vs. placebo: 0.86 (0.30-2.44) p-value: 0.75
		<u>Subgroup, BMI, HR (95% CI):</u> <30 kg/m ² : Metformin vs. placebo: 0.81 (0.44-1.47) ≥30 kg/m ² : Metformin vs. placebo: 0.44 (0.24-0.80) p-value: 0.15 <30 kg/m ² : Fluvoxamine vs. placebo: 1.51 (0.65-3.48) ≥30 kg/m ² : Fluvoxamine vs. placebo: 1.26 (0.61-2.62) p-value: 0.75 <30 kg/m ² : Ivermectin vs. placebo: 1.08 (0.51-2.26) ≥30 kg/m ² : Ivermectin vs. placebo: 0.85 (0.41-1.73) p-value: 0.64
		<u>Subgroup, Time from symptom onset to first dose of study drug (days), HR (95% CI):</u> ≤3 days: Metformin vs. placebo: 0.37 (0.15-0.95) ≥4 days: Metformin vs. placebo: 0.66 (0.41-1.06) p-value: 0.27 ≤3 days: Fluvoxamine vs. placebo: 1.47 (0.42-5.23)

		<p>≥ 4 days: Fluvoxamine vs. placebo: 1.32 (0.72-2.43) p-value: 0.88</p> <p>≤ 3 days: Ivermectin vs. placebo: 0.80 (0.30-2.12) ≥ 4 days: Ivermectin vs. placebo: 1.00 (0.54-1.82) p-value: 0.70</p> <p><u>Subgroup, Age groups:</u></p> <p><45 years: Metformin vs. placebo: 0.39 (0.20-0.73) ≥ 45 years: Metformin vs. placebo: 0.85 (0.48-1.51) p-value: 0.07</p> <p><45 years: Fluvoxamine vs. placebo: 0.87 (0.37-2.07) ≥ 45 years: Fluvoxamine vs. placebo: 1.78 (0.84-3.77) p-value: 0.22</p> <p><45 years: Ivermectin vs. placebo: 1.00 (0.51-1.98) ≥ 45 years: Ivermectin vs. placebo: 0.93 (0.42-2.04) p-value: 0.89</p> <p><u>Subgroup, Dominant SARS-CoV-2 variant at time of randomization, HR (95% CI):</u></p> <p>Alpha: Metformin vs. placebo: 0.21 (0.02-1.87) Delta: Metformin vs. placebo: 0.68 (0.42-1.12) Omicron: Metformin vs. placebo: 0.45 (0.18-1.11) p-value: 0.41</p> <p>Alpha: Fluvoxamine vs. placebo: 0.42 (0.04-4.67) Delta: Fluvoxamine vs. placebo: 1.35 (0.73-2.48) Omicron: Fluvoxamine vs. placebo: 2.32 (0.45-11.94) p-value: 0.48</p> <p>Alpha: Ivermectin vs. placebo: 0.15 (0.00-6.17)</p>
--	--	---

		<p>Delta: Ivermectin vs. placebo: 1.25 (0.68-2.32)</p> <p>Omicron: Ivermectin vs. placebo: 0.60 (0.21-1.69)</p> <p>p-value: 0.08</p> <p><u>Subgroup, SARS-CoV-2 vaccination status, HR (95% CI):</u></p> <p>Not vaccinated: Metformin vs. placebo: 0.44 (0.24-0.80)</p> <p>Vaccinated: Metformin vs. placebo: 0.85 (0.46-1.57)</p> <p>p-value: 0.12</p> <p>Not vaccinated: Fluvoxamine vs. placebo: 1.19 (0.52-2.71)</p> <p>Vaccinated: Fluvoxamine vs. placebo: 1.50 (0.72-3.14)</p> <p>p-value: 0.68</p> <p>Not vaccinated: Ivermectin vs. placebo: 1.18 (0.60-2.30)</p> <p>Vaccinated: Ivermectin vs. placebo: 0.65 (0.28-1.49)</p> <p>p-value: 0.27</p>
Ko, 2022	1. Steroids 2. Antivirals 3. Hydroxychloroquine	<p><u>Sensitivity analysis by ICU population, OR (95% CI):</u></p> <p>ICU patients: 1.26 (0.51–3.11)</p> <p>p-value: 0.62</p> <p><u>Sensitivity analysis by non-invasive mechanical ventilation population, OR (95% CI):</u></p> <p>Non-invasive mechanical ventilation patients: 0.49 (0.13-1.88)</p> <p>p-value: 0.30</p> <p><u>Sensitivity analysis by mechanical ventilation population, OR (95% CI):</u></p> <p>Mechanical ventilation patients: 2.25 (0.21-23.87)</p> <p>p-value: 0.50</p>
Nevalainen, 2022	Antivirals	<p><u>Subgroup, need for oxygen therapy, RR (95% CI):</u></p> <p>Oxygen during admission: 1.03 (0.90-1.17)</p> <p>No oxygen during admission: 0.88 (0.65-1.18)</p>

Table S6. Subgroup data, secondary outcomes

Author, Year	Secondary outcome		Subgroups/sensitivity analyses
Chuang, 2023	Hospitalizations	Antivirals	<p><u>Subgroup, Age groups, OR (95% CI):</u></p> <p>≥65 years: 0.476 (0.365-0.620)</p> <p>45–64 years: 0.333 (0.234-0.473)</p> <p>18–44 years: 0.532 (0.373-0.759)</p> <p>p-value: <0.001</p> <p><u>Subgroup, Sex, OR (95% CI):</u></p> <p>Male: 0.588 (0.444-0.779)</p> <p>Female: 0.398 (0.314-0.505)</p> <p>p-value: <0.001</p> <p><u>Subgroup, Vaccination status, OR (95% CI):</u></p> <p>Unvaccinated: 0.375 (0.294-0.488)</p> <p>Vaccinated: 0.759 (0.569-1.011)</p> <p>p-value: <0.001</p>
Chuang, 2023	Fatigue	Antivirals	<p><u>Subgroup, Age groups, OR (95% CI):</u></p> <p>≥65 years: 0.952 (0.741-1.224)</p> <p>45–64 years: 0.735 (0.558-0.966); p-value: <0.05</p> <p>18–44 years: 0.845 (0.578-1.236)</p> <p><u>Subgroup, Sex, OR (95% CI):</u></p> <p>Male: 0.902 (0.697-1.167)</p> <p>Female: 0.797 (0.644-0.988)</p> <p>p-value: <0.05</p>

			<p><u>Subgroup, Vaccination status, OR (95% CI):</u></p> <p>Unvaccinated: 0.913 (0.731-1.149)</p> <p>Vaccinated: 0.833 (0.646-1.073)</p> <p>p-value: >0.05</p>
Chuang, 2023	Cognitive impairments	Antivirals	<p><u>Subgroup, Age groups, OR (95% CI):</u></p> <p>≥65 years: 0.931 (0.669-1.297)</p> <p>45–64 years: 0.540 (0.275-1.063)</p> <p>18–44 years: 0.769 (0.336-1.754)</p> <p>p-value: >0.05</p> <p><u>Subgroup, Sex, OR (95% CI):</u></p> <p>Male: 0.657 (0.417-1.036)</p> <p>Female: 0.862 (0.614-1.209)</p> <p>p-value: >0.05</p> <p><u>Subgroup, Vaccination status, OR (95% CI):</u></p> <p>Unvaccinated: 0.742 (0.527-1.053)</p> <p>Vaccinated: 0.600 (0.394-0.915)</p> <p>p-value: <0.05</p>
Chuang, 2023	Anxiety/depression (Patel 2024 used for this outcome from TriNetX database)	Antivirals	<p><u>Subgroup, Age groups, OR (95% CI):</u></p> <p>≥65 years: 1.211 (0.986-1.488)</p> <p>45–64 years: 1.037 (0.860-1.253)</p> <p>18–44 years: 1.085 (0.890-1.323)</p> <p>p-value: >0.05</p> <p><u>Subgroup, Sex, OR (95% CI):</u></p> <p>Male: 0.941 (0.765-1.157)</p> <p>Female: 1.140 (0.997-1.304)</p> <p>p-value: >0.05</p>

			<u>Subgroup, Vaccination status, OR (95% CI):</u> Unvaccinated: 0.982 (0.846-1.136) Vaccinated: 1.088 (0.920-1.287) p-value: >0.05
--	--	--	---




Figure S1. PCC by antibiotic use




Figure S2. PCC by antibiotic use (sensitivity analysis, excluding non-recovery study [Evans 2021])




Figure S3. Fatigue by antiviral use




Figure S4. Fatigue by steroid use




Figure S5. Fatigue by steroid use (continuous)




Figure S6. Breathlessness/Dyspnea by steroid use




Figure S7. Cognitive impairment by antiviral use




Figure S8. Health-related quality of life by steroid use

Searches

Table S7. Search for Medline [Ovid]

Ovid MEDLINE(R) ALL <1946 to February 09, 2024>

1	Post-Acute COVID-19 Syndrome/ and (pc or th).fs.	413
2	((post covid* or post coronavirus* or long covid* or long coronavirus*) adj2 (prevent* or prophyla* or treatment* or management*)).ab.	322
3	1 or 2	709
4	Post-Acute COVID-19 Syndrome/	2985
5	(long COVID* or long coronavirus* or longCOVID* or longcoronavirus*).ti,ab,kf.	4733
6	(sequela* adj5 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV or SARSCOV-2 or SARSCOV2)).ti,ab,kf.	2682
7	((post or chronic or long term or longterm or persistent*) adj3 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV2 or SARSCOV-2 or SARSCOV2) adj4 (condition* or sequela* or syndrome* or subsyndrome* or clinical syndrome* or disorder* or symptom* or outcome* or clinical outcome* or function* or followup or follow-up or subtyp* or sub-typ* or phenotyp* or complication* or survivor*)).ti,ab,kf.	5003
8	((post acute or postacute or late complication*) adj3 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV2 or SARSCOV-2 or SARSCOV2)).ti,ab,kf.	1860
9	PASC.ti,kf.	369
10	post-COVID*.kf.	1769
11	or/4-10	10222
12	COVID-19/ or SARS-CoV-2/	260259
13	(COVID* or coronavirus* or corona virus* or 2019nCoV or 19nCoV or COVID19* or COVID or SARS-COV-2 or SARSCOV-2 or SARS-COV2 or SARSCOV2 or SARS coronavirus 2 or Severe Acute Respiratory Syndrome Coronavirus 2 or Severe Acute Respiratory Syndrome Corona Virus 2).ti,ab,kf,nm,ot,ox,rx,px.	419256
14	12 or 13	424813
15	((post acute or postacute or sub-acute or subacute or chronic or long or longterm or late) adj sequela*) or PASC).ti,ab,kf.	4057
16	(long haul* or longhaul*).ti,ab,kf.	1360
17	((persist* or long* or residual or prolonged) adj8 ((olfactory or chemosensor*) adj (disorder* or dysfunction*))).ti,ab,kf.	237
18	(post* or chronic* or long or longterm or sequela*).ti,ab,kf.	5904171
19	(PFS or (pulmonary adj3 fibro*) or (lung adj3 fibro*) or fatigue syndrome? or myalgic encephalomyelitis or ME-CFS or ME?CFS or (postural adj3 tachycardia*) or POTS or MIS-C or MIS-A or PIMS or PIMSTS or PIMS-TS).ti,ab,kf.	106191
20	((multisystem* or multi-system*) adj3 (inflamm* or hyperinflamm*)).ti,ab,kf.	4302

21	18 and (19 or 20)	33771
22	or/15-17,21	39152
23	14 and 22 [adapted from CADTH Literature Search Strategy - Post-COVID-19 Condition Treatment and Management Rapid Scoping Review]	3470
24	exp vitamins/	357185
25	exp vitamin b 6/	16870
26	exp vitamin b 12/	24019
27	exp riboflavin/	15829
28	exp niacinamide/	17447
29	exp thiamine/	12590
30	exp folic acid/	42459
31	exp ascorbic acid/	45940
32	exp Dietary Supplements/	103759
33	vitamin?.tw,kf.	261733
34	riboflavin.tw,kf.	12151
35	(niacinamide or enduramide or nicobion or nicotinamide or papulex).tw,kf.	27099
36	(thiamine or aneurin or thiamin).tw,kf.	14892
37	(folic acid or folacin or folate or folvite or pteroylglutamic acid).tw,kf.	49508
38	(ascorbic acid or ferrous ascorbate or hybrin or "l-ascorbic acid" or magnesium ascorbate or magnesium ascorbicum or "magnesium di-l-ascorbate" or magnorbin or sodium ascorbate).tw,kf.	39929
39	((diet* or nutrition* or herbal* or food?) adj3 supplement*).tw,kf.	80615
40	exp Probiotics/ or probiotic*.tw,kf.	45818
41	Zinc/	68000
42	Magnesium/	70431
43	Selenium/ or selenium*.tw,kf.	40905
44	(mineral* or zinc or magnesium).tw,kf.	421275
45	Ubiquinone/ or "coenzyme q10".tw,kf.	12120
46	exp Diet Therapy/ or ((diet* or nutrition*) adj2 (advice* or therap* or counsel* or change* or intervention* or program*)).tw,kf. or (dietitian* or nutritionist*).tw,kf.	137402
47	exp anti-inflammatory agents/	576037
48	((antiinflammator* or anti inflammator*) adj2 (d rug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)) or NSAID or NSAIDs).tw,kf.	47269

49	exp adrenal cortex hormones/	428303
50	(adrenal cortex hormone? or corticoid? or cortical steroid? or cortico steroid? or corticosteroid? or dermocorticosteroid?).tw,kf.	140188
51	(dexamethasone? or decaject? or decameth? or decaspray? of dexasone? or dexpak? or hexadecadrol? or hexadrol? or maxidex? or methylfluorprednisolone? or millicorten? or oradexon?).tw,kf.	66806
52	(prednisone or cortan or cortancyl or cutason or dacortin or decortin or decortisyl or dehydrocortisone or deltasone or encorton or encortone or enkortolon or kortancyl or liquid pred or meticorten or orasone or panafcort or panasol or predni tablinen or prednidib or predniment or prednison acsis or prednison galen or prednison hexal or pronisone or rectodelt or sone or sterapred or ultracorten or winpred or delta cortisone).tw,kf.	33245
53	(methylprednisolone or methylprednisolone or medrol or metipred or urbason).tw,kf.	20354
54	(hydrocortisone or "acticort" or "aeroseb hc" or "ala-cort" or "ala-scalp" or "alfacort" or "alcicortis" or "alkindi" or "alpha derm" or "alphaderm" or "anucort-hc" or "anumed-hc" or "anutone-hc" or "aquanil hc" or "balneol-hc" or "barseb hc" or "beta-hc" or "biacort" or "cetacort" or "cobadex" or "colocort" or "compound f" or "cordicare lotion" or "coripen" or "cort dome" or "cortef" or "cortef cream" or "cortenema" or "cortibel" or "corticorenol" or "cortifan" or "cortiphate" or "cortisol" or "cortisole" or "cortispray" or "cortoderm" or "cortril" or "cotacort" or "covocort" or "cremicort-h" or "cutaderm" or "dermacrin hc lotion" or "dermaid" or "derm-aid cream" or "dermaid soft cream" or "dermocare" or "dermcortal" or "dermolate" or "diaderm" or "eczacort" or "ef cortelan" or "efcortelan" or "egocort" or "egocort cream" or "eksalb" or "eldecort" or "emo-cort" or "epicort" or "ficortril" or "filocot" or "flexicort" or "glycort" or "gly-cort" or "hc no. 1" or "hc no. 4" or "h-cort" or "hebcort" or "hebcort v" or "hemorrhoidal hc" or "hemril-30" or "hemril-hc uniserts" or "hi-cor" or "hidrotisona" or "hycor" or "hycort" or "hydracort" or "hydrasson" or "hydro ricortex" or "hydrocort" or "hydrocorticosteroid" or "hydrocortisate" or "hydrocortison" or "hydrocortisonum" or "hydrocortisy" or "hydrocortone" or "hydrogalen" or "hydrokort" or "hydrokortison" or "hydro-rx" or "hydrotopic" or "hysone" or "hytisone" or "hytone" or "hytone lotion" or "incortin h" or "instacort 10" or "kyppakkaus" or "lacticare hc" or "lemnis fatty cream hc" or "lenirit" or "medihaler cort" or "medihaler duo" or "medrocil" or "mildison" or "mitocortyl demangeaisons" or "munitren" or "nogenic hc" or "novohydrocort" or "nsc 10483" or "nsc 741" or "nsc10483" or "nutracort" or "optef" or "otosone f" or "penecort" or "plendren" or "prepcort" or "prevex hc" or "pro cort" or "procort" or "proctocort" or "proctosert hc" or "proctosol-hc" or "proctosone" or "proctozone hc" or "procutan" or "rectasol-hc" or "rectocort" or "rederm" or "sanatison" or "scalp-aid" or "schericur" or "schericur 0.25%" or "scherosone f" or "sistral hydrocort" or "skincalm" or "stie-cort" or "substance m" or "synacort" or "texacort" or "triburon-hc" or "unicorn" or "vasocort").tw,kf.	89634
55	nitric oxide/	97093
56	(nitric oxide or endogenous nitrate vasodilator or mononitrogen monoxide or nitrogen monoxide or genosyl or inomax or noxivent).tw,kf.	169020
57	exp prednisolone/	54193
58	(prednisolone or "adelcort" or "antisolon" or "antisolone" or "aprednislone" or "aprednisolone" or "benisolone" or "benisolone" or "berisolone" or "berisolone" or "caberdelta" or "capsoid" or "codelcortone" or "co-hydeltra" or "compresolon" or "cortadeltona" or "cortadeltone" or "cortalone" or "cortelinter" or "cortisolone" or "citolone" or "dacortin" or "dacortin h" or "dacratin" or "decaprednil" or "decortin h" or "decortril" or "dehydro cortex" or "dehydro hydrocortison" or "dehydro hydrocortisone" or "dehydrocortex" or "dehydrocortisol" or "dehydrocortisole" or "dehydrohydrocortison" or "dehydrohydrocortisone" or "delcortol" or "delta 1 hydrocortisone" or "delta cortef" or "delta cortril" or "delta ef cortelan" or "delta f" or "delta hycortol" or "delta hydrocortison" or "delta hydrocortisone" or "delta ophticor" or "delta stab" or "delta1 dehydrocortisol" or "delta1 dehydrohydrocortisone" or "delta1 hydrocortisone" or "deltacortef" or "deltacortenolo" or "deltacortil" or "deltacortoil" or "deltacortril" or "deltaderm" or "deltaglycortil" or "deltahycortol" or "deltahydrocortison" or "deltahydrocortisone" or "deltaopticor" or "deltasolone" or "deltastab" or "deltidrosol" or "deltisolone" or "deltisolon" or "deltisolone" or "deltolasson" or "deltolassone" or "deltosona" or "deltosone" or "depo-predate" or "dermosolon" or "dhasolone" or "di adreson f" or "di adresone f" or "diadreson f" or "diadresone f" or "dicortol" or "domucortone" or "encortelon" or "encortelone" or	33244

"encortolon" or "equisolon" or "fernisolone-p" or "glistelone" or "hefasolon" or "hostacortin h" or "hostacortin h vet" or "hydeltra" or "hydeltrone" or "hydrelta" or "hydrocortancyl" or "hydrocortidelt" or "hydrodeltalone" or "hydrodeltisone" or "hydroretrocortin" or "hydroretrocortine" or "inflanefran" or "insolone" or "ketecort h" or "keypred" or "lenisolone" or "leocortol" or "liquipred" or "lygal kopftinktur n" or "mediasolone" or "meprisolon" or "meprisolone" or "metacortalon" or "metacortalone" or "metacortandralon" or "metacortandralone" or "metacortelone" or "meti derm" or "meticortelone" or "metiderm" or "morlone" or "mydrapred" or "neo delta" or "nisolon" or "nisolone" or "nsc 9120" or "nsc9120" or "opredsone" or "panafcortelone" or "panafcortolone" or "panafort" or "paracortol" or "phlogex" or "pre cortisyl" or "preconin" or "precortalon" or "precortancyl" or "precortisyl" or "predacort 50" or "predaject-50" or "predalone 50" or "predartrina" or "predartrine" or "predate-50" or "predeltilone" or "predisole" or "predisy" or "pred-ject-50" or "predne dome" or "prednecort" or "prednedome" or "prednelan" or "predni coelin" or "predni h tablinen" or "prednicolin" or "prednicort" or "prednicortelone" or "prednifor drops" or "predni-helvacort" or "predniment" or "predniretard" or "prednis" or "prednisil" or "prednisolon" or "prednisolona" or "prednisolone alcohol" or "prednisolone h" or "prednisolone oleosae sr 82" or "prednivet" or "prednorsolon" or "prednorsolone" or "predonine" or "predorgasolona" or "predorgasolone" or "prelon" or "prelon" or "prenilone" or "prenin" or "prenolone" or "preventan" or "prezolon" or "rubycort" or "scherisolon" or "scherisolona" or "serilone" or "solondo" or "solone" or "solupren" or "soluprene" or "spiricort" or "spolotane" or "sterane" or "sterolone" or "supercortisol" or "supercortizol" or "taracortelone" or "walesolone" or "wysolone").tw,kf.

59	exp aspirin/	49059
60	(aspirin or acetylsalicylic acid or "8-hour bayer" or "acenterine" or "acesal" or "acetan" or "acetard" or "acetil" or "aceticyl" or "acetilum" or "acetonyl" or "acetophen" or "acetosal" or "acetosalicylic acid" or "acetosalin" or "acetosalum" or "acetyl salicylate" or "acetyl salicylic acid" or "acyticlic salicylic acid" or "acetylin" or "acetylo" or "acetylo salicylic acid" or "acetylon" or "acetylosalicylic acid" or "acetylsal" or "acetylsalicyclic acid" or "acetylsalicyl" or "acetylsalicylate" or "acetylsalicylate strontium" or "acetylsalicylic acid plus glycine" or "acetylsalicylic acid sodium salt" or "acetylsalicylic acid strontium salt" or "acetylsalycic acid" or "acetylsalicylic acid" or "acetsal" or "acidulatum" or "acidum acetyl salicylicum" or "acidum acetylosalicylicum" or "acidum acetylsalicylicum" or "actorin" or "acylpyrin" or "acylpyrine" or "acytosal" or "adiro" or "alabukun" or "alasil" or "albyl e" or "albyl minor" or "alka seltzer" or "alkaspirin" or "anasprin" or "andol" or "anopyrin" or "ansin" or "anthrom" or "aptor" or "arthralgyl" or "arthritis strength bufferin" or "asacard" or "asaetta" or "asaflow" or "asaphen" or "asapor" or "asatard" or "asawin" or "aspec" or "aspent" or "aspergum" or "aspex" or "aspilets" or "aspirem" or "aspirgran" or "aspiricor" or "aspirina" or "aspirine" or "aspirinine" or "aspirisucre" or "aspisol" or "aspoc cid" or "aspro" or "aspro cardio" or "aspro clear" or "asproflash" or "asrina" or "asrivo" or "asta" or "astic" or "astic acid" or "astrix" or "bamyl" or "bayaspirina" or "bebesan" or "biprin" or "bokey" or "boxazin" or "breoprin" or "bufferin" or "cafenol" or "cardioasa" or "cardiosae" or "cardioaspirina" or "cartia" or "caspirin" or "catalgine" or "catalgix" or "cemerit" or "cemirit" or "claradin" or "claragine" or "colfarit" or "comoprin" or "contrheuma" or "contrheuma retard" or "darosal" or "depot aspirin" or "dispirin" or "dolean" or "durlaza" or "dusil" or "easprin" or "ecasil" or "ecosprin" or "ecotrin" or "egalgic" or "emocin" or "empirin" or "encaprin" or "encine em" or "endosprin" or "entaprin" or "entericin" or "enteroprin" or "enterosarine" or "enterospirine" or "entrophen" or "eskotrin" or "euthermine" or "extren" or "flamasacard" or "genasprin" or "globentyl" or "godamed" or "gotosan" or "helicon" or "herz ass" or "hjertemagnyl" or "idotyl" or "infatabs a" or "istopirin" or "istopyrine" or "ivepirine" or "juvepirine" or "keypo" or "kilios" or "kinderaspirin" or "magnecyl brus" or "magnyl dak" or "mcn r 358" or "measurin" or "mejoral" or "melabon" or "micristin" or "micropyrin" or "migrasaa" or "mikristin" or "miniasal" or "mycristin" or "naspro" or "novasen" or "nu seal" or "nuseals" or "nu-seals" or "nu-seals asa" or "ortho acetoxybenzoate" or "ortho acetoxybenzoic acid" or "ortho acetyloxybenzoate" or "ortho acetyloxybenzoic acid" or "ostoprin" or "pancemol" or "para acetylsalicylic acid" or "paracin" or "paynocil" or "pengo" or "platet 300 cleartab" or "plewin" or "polopiryna" or "premaspin" or "primaspan" or "proprin" or "pyronoval" or "reumyl" or "rhodine" or "rhonal" or "ronal" or "salacetin" or "salacetogen" or "saletin" or "salisalido" or "salospir" or "sargepirine" or "sedergine" or "sedergine forte" or "sodium acetylsalicylate" or "sodium bicarbonate acetyl salicylate" or "sodium bicarbonate acetylsalicylate" or "soldral" or "solpyron" or "solucetyl" or "solupsa" or "spren" or "super tru" or "tapal" or "temagin" or "tevapirin" or "th 2152" or "thrombo-aspilets" or "toldex retard" or "treupahlin" or "treuphalin" or "tromalyt" or "tromcor" or "turivital" or "vazalore" or "verin" or "vitalink" or "xaxa" or "zorprin").tw,kf.	66766
61	(adalimumab or "abp 501" or "abp501" or "abrilada" or "abt d2e7" or "abtd2e7" or "adaly" or "amgevita" or "amjevita" or "amsparity" or "avt 02" or "avt02" or "bat 1406" or "bat1406" or "bax 2923" or "bax 923" or "bax2923" or "bax923" or "bi 695501" or "bi695501" or "chs 1420" or "chs1420" or "cinnora" or "ct p17" or "ctp17" or "cyltezo" or "da 3113"	10030

or "da3113" or "dmb 3113" or "dmb3113" or "exemptia" or "fkb 327" or "fkb327" or "fyzoclad" or "gp 2017" or "gp2017" or "hadlima" or "halimatoz" or "hefiya" or "hlx 03" or "hlx03" or "hulio" or "humira" or "hyrimoz" or "ibi 303" or "ibi303" or "idacio" or "imraldi" or "kromeya" or "lu 200134" or "lu200134" or "m 923" or "m923" or "mabura" or "monoclonal antibody d2e7" or "msb 11022" or "msb11022" or "ons 3010" or "ons3010" or "pf 06410293" or "pf 6410293" or "pf06410293" or "pf6410293" or "raheara" or "sb 5" or "sb5" or "solymbic" or "trudexa" or "zrc 3197" or "zrc3197").tw,kf.

62	(celecoxib or "aclarex" or "artilog" or "artroxil" or "caditar" or "celcox" or "celebra" or "celebreks" or "celebrex" or "celecox" or "celib" or "celora" or "coxel" or "coxit" or "dilox" or "eliflam" or "elyxyb" or "lexfin" or "onsenal" or "sc 58635" or "sc58635" or "solexa" or "ym 177" or "ym177" or "zycel").tw,kf.	8420
63	(diclofenac or "abdiflam" or "abitren" or "acuflam" or "akis" or "algipatch" or "algistick" or "algopain eze" or "algoplast" or "allvoran" or "almiral" or "alonpin" or "antalcalm" or "apo-diclofenac ec" or "arcanafenac" or "arthrif'en" or "artren" or "artrenac" or "artrites" or "assaren" or "athrofen" or "ba 47210" or "ba47210" or "berafen gel" or "berifen" or "betaren" or "bolabomin" or "calozan" or "catanac" or "catas" or "cencenag" or "clo-far" or "clofec" or "clofen" or "clonac" or "clonaren" or "clonodifen" or "cordralan" or "curinflam" or "ddl plaster" or "declophen" or "decrol" or "deflamat" or "deflam-k" or "delphinac" or "denaclof" or "depain" or "diceus" or "dicipan" or "diclac" or "diclax" or "diclo" or "diclobasan" or "diclobene" or "diclod" or "dicloden" or "diclodoc" or "diclodolor" or "diclofen" or "diclofen cremogel" or "diclofenac rekur" or "diclofenac resin" or "diclofenac resinate" or "diclofenac sodium" or "dicloflam" or "diclohexal" or "dicloin" or "diclomax" or "diclomol" or "diclon" or "diclopax" or "diclophenac sodium" or "diclopuren" or "dicloral" or "dicloran gel" or "diclorecip" or "dicloren" or "diclorem" or "diclosan sr" or "diclosian" or "diclotec" or "diclowal" or "dicsnal" or "difen" or "difena" or "difenac" or "difenol gel" or "difnal k" or "dioxaflex" or "dioxaflex retard" or "divoltar" or "dixol" or "doflastad" or "doflex" or "dolaren" or "dolflam-retard" or "dolo voltaren" or "doloflam" or "dolotren" or "doragon" or "dosanac" or "duravolten" or "dycon sr" or "dyloject" or "ecofenac" or "econac" or "effekton" or "eflagen" or "epifenac" or "eslofen" or "evadol" or "evinopon" or "feloran" or "fenac" or "fenadium" or "fenaspec" or "flameril" or "flexagen" or "flogofenac" or "flogosin d" or "flogozan" or "fortfen sr" or "freejex" or "gp 45840" or "grofenac" or "hizemin" or "imflac" or "inac gel" or "indicam" or "inflamac" or "inflanac" or "isv 205" or "isv205" or "jonac gel" or "kadiflam" or "kinespir" or "klofen l" or "klotaren" or "kriplex" or "lesflam" or "leviogel" or "lifenac" or "lofenac" or "lotirac" or "magluphen" or "merflam" or "modifenac" or "monoflam" or "motifene" or "naboal" or "nac gel" or "naclof" or "nacoflar" or "nadifen" or "novapirina" or "novo-difenac" or "novolten" or "ufenac" or "olen" or "optanac" or "orthophen" or "osteoflam" or "paintstop" or "panamor" or "pennsaid" or "profenac" or "relaxyl gel" or "remethan" or "renvol emulgel" or "rewodina" or "rheufenac" or "rheumafen" or "rheumatac" or "rheumatac retard" or "rhewlin" or "rhewlin sr" or "rhumalgan" or "rolactin" or "sailib" or "savism" or "sefnac" or "slofenac" or "sodium diclofenac" or "solaraze" or "sophenoderm" or "soproxen" or "spraymik" or "sr 318t" or "staren" or "sting gel" or "tabiflex" or "tds 943" or "tds943" or "tigen plaster" or "toraren" or "traulen" or "tsudohmin" or "uniconanax" or "uniren" or "valentac" or "vartelon" or "veral" or "voldal" or "voldic" or "volero" or "volfenac" or "volna-k" or "volsaid" or "volta" or "voltadex emulgel" or "voltadvance" or "voltalen" or "voltalen emulgel" or "voltalgan" or "voltaren" or "voltarene" or "voltarensp" or "voltarol" or "voltine" or "voltral" or "voltrix" or "voren emulgel" or "votalen" or "vooveran" or "vurdon" or "wergyl" or "xenid" or "yuren" or "zolterol" or "zorvoalex").tw,kf.	15849
64	dimethyl sulfoxide/	15968
65	(dimethyl sulfoxide or "damul" or "demasorb" or "demavet" or "demeso" or "demexide" or "dimethyl sulphoxide" or "dimethylsulfoxide" or "dimethylsulphoxide" or "dimexide" or "dms 70" or "dms 90" or "dms70" or "dms90" or "dms0" or "dolicur" or "domoso" or "dromisol" or "gamasal 90" or "hyadur" or "infiltrina" or "methyl sulfoxide" or "methylsulfoxide" or "nsc 763" or "nsc763" or "rimso 100" or "rimso 50" or "somipront" or "sq 9453" or "sq9453" or "syntexan").tw,kf.	35198
66	(indomethacin or " algiflam" or "algometacin" or "amuno" or "antalgin dialicels" or "apo-indomethacin" or "areumatin" or "argilex" or "arthrexin" or "articulen" or "artracin" or "artrilona s" or "artrinovo" or "artrocid" or "asimet" or "benocid" or "betacin" or "bonidon" or "bouycin" or "catlep" or "chrono indocid" or "chronoindocid" or "confortid" or "docin" or "dolazal" or "dolazol" or "dolcidium" or "dometin" or "durametacin" or "elmego spray" or "elmetacin" or "endometacin" or "flamaret" or "flexin continu" or "grindocin" or "helvecin" or "idicin" or "im-75" or "imbrilon" or "imet" or "inacid" or "indacin" or "indalgin" or "inderapollon" or "indicin" or "indo phlogont" or "indocap" or "indocid"	37942

or "indocin" or "indocolir" or "indocollyre" or "indogesic" or "indolag" or "indolar sr" or "indolemmon" or "indolemmon" or "indomecin" or "indomed" or "indomee" or "indomelan" or "indomelol" or "indomet retard" or "indometacin sodium" or "indometacine" or "indomethacin" or "indomethechine" or "indomethacinum" or "indomethegan" or "indometricina mckesson" or "indometin" or "indometin depot" or "indomexum" or "indomin" or "indono" or "indoptic" or "indoptol" or "indorektal" or "indorem" or "indos" or "indosan" or "indosima" or "indosmos" or "indo-tablinen" or "indotard" or "indovis" or "indoxen" or "indoy" or "indren" or "indrenin" or "indylon" or "inflazon" or "inmetsin" or "inteban" or "lauzit" or "luiflex" or "lyo indometacin trihydrate" or "malival" or "mcn r 1166" or "mcn r1166" or "metacen" or "methacin" or "methindol" or "methindole" or "methocaps" or "metindol" or "mezolin" or "miometacen" or "mk 615" or "mk615" or "mobilan" or "novomethacin" or "osmogit" or "osmosin" or "reumacid" or "reusin" or "rheumacid" or "rheumacin" or "salinac" or "servimeta" or "sidocin" or "tannex" or "taye" or "tivorbex" or "vi-gel" or "vonusum").tw,kf.

67	methotrexate/	41832
68	(methotrexate or "abitrexate" or "amethopterin" or "amethopterine" or "ametopterine" or "antifolan" or "biotrexate" or "canceren" or "cl 14377" or "cl14377" or "emtexate" or "emthexat" or "emthexate" or "emtrexate" or "enthexate" or "farmitrexat" or "farmitrexate" or "farmotrex" or "folex" or "ifamet" or "imeth" or "intradose mtx" or "jylamvo" or "lantarel" or "ledertrexate" or "maxtrex" or "metex" or "methoblastin" or "methohexate" or "methotrate" or "methotrexat" or "methotrexato" or "methoxtrexate" or "methrotrexate" or "methylaminopterin" or "methylaminopterine" or "meticil" or "metoject" or "metothrexate" or "metotrexat" or "metotrexate" or "metotrexin" or "metrex" or "mexate" or "mpi 5004" or "mpi5004" or "neotrexate" or "nordimet" or "novatrex" or "nsc 740" or "nsc740" or "otrexup" or "otrexup pfs" or "rasuovo" or "reditrex" or "reumatrex" or "rheumatrex" or "texate" or "texorate" or "trexall" or "xaken" or "xatmep" or "zexate").tw,kf.	49125
69	(naproxen or "acusprain" or "aflamax" or "aflaxen" or "agilex" or "agilxen" or "aleve" or "alpoxen" or "alpron" or "anaprox" or "anexopen" or "apo-naproxen" or "apranax" or "apraxin" or "apronax" or "artagen" or "artron" or "artroxen" or "axer alfa" or "babel" or "bipronyl" or "bonyl" or "congex" or "crysanal" or "dafloxa" or "daproxi" or "daproxi entero" or "deflamox" or "dextro naproxen" or "diferbest" or "diocodal" or "dolormin fuer Frauen" or "dolormin fur Frauen" or "dolormin gs" or "dysmenalgit" or "dysmenalgit n" or "ec naprosyn" or "equiproxen" or "femex" or "feminax ultra" or "flanax" or "flanax forte" or "floginax" or "flonax" or "floxene" or "fuxen" or "galpharm period pain relief" or "gibixen" or "headlon" or "iraxen" or "laraflex" or "lasonil antinfiammatorio e antireumatico" or "lefaine" or "leniartil" or "levo naproxen" or "licorax" or "methoxypropiocin" or "miranax" or "momendol" or "nafasol" or "naixan" or "napolon" or "naposin" or "napreben" or "naprelan" or "napren" or "naprium" or "naprius" or "naproflam" or "naprogesic" or "naprong" or "naprontag" or "naproxen" or "naprossene" or "naprostad" or "naprosyn" or "naprosyne" or "naprovite" or "naproxeno" or "naproxi 250" or "naproxi 500" or "naproxyn" or "naprozyne" or "naprux" or "napsyn" or "napxen" or "naroma" or "narocin" or "naxen" or "naxopren" or "naxyn" or "neprossin" or "norswel" or "novonaprox" or "novo-naprox" or "novuran" or "nuprafem" or "nycopren" or "pactens" or "prexan" or "priaxen" or "prodilor" or "pronaxen" or "proxen" or "proxidol" or "rahsen" or "rs 3540" or "rs 3650" or "rs3540" or "rs3650" or "sanomed" or "saritilron" or "seladin" or "shiprosyn" or "sutolin" or "synaprosyn" or "synflex" or "tohexen" or "uniflam" or "u-ritis" or "velsay" or "veradol" or "vinsen" or "wintrex" or "xenar" or "xenobid").tw,kf.	7618
70	Hydroxychloroquine/	5984
71	(hydroxychloroquine or chloroquinol or ercoquin or hydrochloroquine or hydrochloroquine or oxychloroquine or quensyl or sn-8137 or sn8137 or tlc-19 or tlc19 or win-1258 or win1258).tw,kf.	9295
72	exp histamine h1 antagonists/ or exp histamine h2 antagonists/ or antihistamine*.tw,kf.	62316
73	exp antiviral agents/	404812
74	((antivir* or anti vir*) adj2 (drug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)).tw,kf.	29233
75	(tocilizumab or actemra or atlizumab or lusinex or "r 1569" or r1569 or roactemra).tw,kf.	6541
76	(baricitinib or "incb 028050" or "incb 28050" or incb028050 or incb28050 or "ly 3009104" or ly300910 or olumiant).tw,kf.	1458

77	(remdesivir or redyx or ro-7286260 or ro7286260 or veklury or gs-5734 or gs5734).tw,kf.	3809
78	(nirmatrelvir* or pf-07321332 or pf-7321332 or pf07321332 or pf7321332 or paxlovid or ritonavir* or a-84538 or a84538 or abt-538 or abt-84538 or abt538 or abt84538 or norvir or orb-102 or orb102 or ritovir).tw,kf.	9125
79	(favipiravir or avicod or avigan or favicovir or t-705 or t705).tw,kf.	1408
80	(oseltamivir or ebilfumin or en-241104 or en241104 or enzamir or fluvir or gs-4104 or gs4104 or gs4104002 or hgp-0919 or hgp0919 or hip-1403 or hip1403 or oseltamavir or ro-64-0796 or ro640796 or segosana or tamiflu or tamivil).tw,kf.	4595
81	(ganciclovir or gancyclovir or citovirax or cymeven or cymeven* or cytovene or denocin or denosine or dihydroxypropoxymethylguanine or virgan or vitrasert or zirgan).tw,kf.	7781
82	((anticoagulant* or anti coagulant* or antithrombo* or anti-thrombo*) adj2 (drug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)).tw,kf.	11115
83	exp heparin, low-molecular-weight/	14448
84	(low adj3 heparin).tw,kf.	15526
85	(choay or depolymerized heparin or traxyparine).tw,kf.	101
86	(enoxaparin or clexan or clexane or decipar or inhixa or klexane or ledraxen or lovenox or neoparin or qualiopt klinik or thorinane).tw,kf.	5596
87	Azithromycin/	6976
88	(azithromycin or aratro or aruzilina or atizor or azacid or azadose or azasite or azatril or azenil or azi-sandoz or azi-teva or azibactron or azibiot or azimed or azimin or azimycin or aziprome or azirox or azirutec or azithral or azithran or azitredil or azitrocin or azitromax or azitromicin* or azitrox or azivirus or aziwill or aziwok or azomyne or azromax or aztrin or azycyna or azyldrop or azylung or azytact or azyter or azythromycin or bactrazol or batif or bazy or bezanin or ciroz or clamelle or goldamycin or inedol or infectoazit or kromicin or macromax or macrozit or makromicin or mezatrin or nobaxin or novozithron or octavax or ordipha or razimax or rezan or ribotrex or sumamed or sunamed or tobly or tromix or trozamil or trozocina or ultreon or vinzam or xithrone or zaraxin or zaret or zarom or zedbac or zetamax or zeto or zibramax or zifin or zimacrol or zimericina or zinfect or zistic or zithrobest or Zithromax* or zithroplus or zithrotel or zithrox or zithroxyn or zitinn or zitrim or zitrobifan or zitrobiotic or zitrocin* or zitrogram or zitronova or zitrozin or zmax).tw,kf.	12609
89	Doxycycline/	11014
90	(Doxycycline or adoxa or amermycin or apprilon or atrax or azudoxat or bactidox or banndoclin or basedillin or bassado or biocolyn or biodoxi or bronmycin or calcium-doxycycline or cloran or cyclidox or dentistar or deoxycycline or deoxymycin dispersal or deoxymykoïn or deoxyoxytetracycline or desoxy oxytetracycline or desoxycycline or doinmycin or dosil or dotur or doxaciclinodoxat or doxatet or doxi-sergo or doxibiotic or doxycycline or doxilin or doximed or doximycin or doxin or doxine or doxirobe or doxycycline or doxsig or doxy or doxybiocin or doxygen or doxygen retard or doxychel or doxycin or doxycyclin or doxylag or doxylin or doxymycin or doxypuren or doxytec or doxytrim or dumoxin or duracycline or efracea or esdoxin or etidoxina or gewacyclin or ibralene or idocyclin or idocyklin or interdoxin or investin or longamycin or lydox or magdrin or medomycin or mespafin or mildox or miraclin or monodox or nanodox or nordox or nsc-56228 or oracea or oraycea or paldomycin or radox or remycin or respidox or roximycin or serodoxy or servidoxine or servidoxyne or siadocin or siclidon or sigadoxin or spanor or supracyclin or supramycin or tenutan or tolexine or torymycin or tsurupioxin or unidox or veemycin or viadoxin or vibra-s or vibrabiotic or vibracina or vibradox or vibramicina or vibramycin* or vibraveineuse or vibravenos or vibravet or viradoxyl-n or wanmycin or xyrosa or zadorin or zenavod).tw,kf.	17639
91	exp Amoxicillin/	12857

92	(actimoxi* or amoxicillin* or amoxil or amoxyccillin* or clamoxyl or hydroxyampicillin or penamox or polymox or trimox or wymox or amox-clav or amoxi-clavulanate or augmentin or clavulin or co-amoxiclav or spektramoxx or synulox).tw,kf.	23075
93	Trimethoprim, Sulfamethoxazole Drug Combination/	7647
94	Vancomycin/	16646
95	(abactrim or bactifor or bactrim or biseptol or centran or centrin or co-trimoxazole or drylin or eslectin or eusaprime or insozalin or kepinol or lescot or metomide or oriprim or septra or septrin or (sulfamethoxazole adj2 trimethoprim) or sulprim or sumetrolim or trimedin or trimethoprim-sulfa or trimezole or trimosulfa or (diatracin or vanco-cell or vanco azupharma or vanco-saar or vancocin* or vancomicina* or vancomycin*)).tw,kf.	50047
96	Ceftriaxone/ or exp Fluoroquinolones/ or exp Cephalosporins/	82384
97	(acantex or axone or benaxona or biotrakson or biotriax or bioxon or broadced or brospec or cef-3 or cefaflox or cefalogen or cefatriaxone or cefaxona or cefaxone or cefin or cefotal or cefotrixon or cefotriaxone or cefriex or ceftrex or ceftrian or ceftriaxone or ceftrilem or cefxon or cephin or cephtriaxone or cerixon or cikedrix or ecotrixon or elpicef or eurocef or ferfacef or forgram or glicocef or gomcephin or grifotriaxona or incephin or keftriaxon or keptrix or lopratin or lyceft or medoxonum or mejion or mesporin or monocef or nakaxone or novosef or oframax or pantrixon or retrokor or rinxofay or rocefalin or rocefin or rocephalin or Rocephin* or rocida or rowcef or roxcef or roxon or samixon or sintrex or socef or sunflow or tacex or torocef-1 or trexofin or triaken or triax or triaxone or tricefin or tricephin or trijec or xtenda or zefaxone or zefone 250).tw,kf.	14042
98	(Fluoroquinolone* or Ciprofloxacin* or Fleroxacin* or Enoxacin* or Enrofloxacin* or Gatifloxacin* or Gemifloxacin* or Moxifloxacin* or Norfloxacin* or Ofloxacin* or Levofloxacin* or Pefloxacin* or (Cephalosporin* or Cefalosporin* or Cefamandoleor* or Cefoperazone* or Cefazolin* or Cefdinir* or Cefepime* or Cefonicid* or Cefsulodin* or Ceftibuten* or Cefuroxime* or Cephacetrile* or Cefotaxime* or Cephalothin* or Cephapirin* or Cephalexin* or Cefaclor* or Cefadroxil* or Cefatrizine* or Cephaloglycin* or Cephadrine* or Cephaloridine* or Ceftazidime* or Cephamycin* or Cefmetazole* or Cefotetan* or Cefoxitin*).tw,kf.	117908
99	Immunomodulating Agents/ or Immunosuppressive Agents/	105945
100	((immunomodula* adj2 (agent* or drug* or medication? or medicine? or compound? or therap*)) or immunomodulator? or immunotherap*).tw,kf.	215369
101	((immunosuppress* or immuno-suppress* or immunodepress*) adj2 (agent* or drug* or medication? or medicine? or compound? or substance? or therap*).tw,kf.	55599
102	Rivaroxaban/	4904
103	(rivaroxaban or assubex or ast-8294 or ast8294 or bay-59-7939 or bay-597939 or bay59-7939 or bay59-7939 or bay597939 or bs-112 or bs112 or dst-8294 or dst8294 or jnj-39039039 or jnj39039039 or kriva or naxat or rivaro or rivarolto or rivaxa or throsaben or xanirva or xarelto or xerdoxo or xindus).tw,kf.	7785
104	Interleukin Inhibitors/	74
105	(interleukin inhibitor? or cytokine antagonist or cytokine receptor block* or interleukin receptor antagonist?).tw,kf.	219
106	((cilgavimab adj2 tixagevimab) or evusheld or "azd 1061 plus azd 8895" or "azd 1061/azd 8895" or azd-7442 or "azd 8895 plus azd 1061" or "azd 8895/azd 1061" or "azd1061 plus azd8895" or "azd1061/azd8895" or azd7442 or "azd8895 plus azd1061" or "azd8895/azd1061").tw,kf.	265
107	(itolizumab or alzumab or bmab-600 or bmab600 or eq-001 or eq001).tw,kf.	62
108	(dupilumab or bat-2406 or bat2406 or dupixent or regn-668 or regn668 or sar-231893 or sar231893).tw,kf.	2845
109	(pamrevlumab or fg-3019 or fg3019).tw,kf.	52

110	exp antibodies, monoclonal/	281491
111	((monoclonal or clonal or hybridoma) adj3 antibod*).tw,kf.	219461
112	(bamlanivimab or etesevimab or "bamlanivimab/etesevimab" or "2423943-37-5" or "LY-3819253" or "LY-COV555" or "LY3819253" or "UNII-45I6OFJ8QH" or "WHO 11876" or "2423948-94-9" or "anti-Sars-cov-2 antibody JS016" or "CB6" or "JS016" or "LY COV016" or "LY-3832479" or "LY-COV016" or "LY3832479" or "NP005" or "UNII-N7Q9NLF11I" or "WHO 11873").tw,kf.	554
113	(casirivimab or imdevimab or "casirivimab/imdevimab" or regen-cov or "REGN-COV2" or regn10933 or regn10987 or "anti-sars-cov-2 regn-cov2" or "2415933-42-3" or "REGN-10933" or "REGN10933" or "UNII-J0FI6WE1QN" or "WHO 11861" or "2415933-40-1" or "REGN-10987" or "REGN10987" or "UNII-2Z3DQD2JHM" or "WHO 11863").tw,kf.	426
114	("Sotrovimab" or "2423014-07-5" or "GSK-4182136" or "GSK4182136" or "UNII-1MTK0BPN8V" or "VIR-7831" or "VIR7831").tw,kf.	333
115	(amubarvimab or "BRII-196" or "BRII-198" or "DZIF-10c" or "BI 767551" or "SCTA01" or "Ty027" or "HLX70").tw,kf.	24
116	("C144-LS" or "C-135-LS" or "C144-LS/C-135-LS").tw,kf.	3
117	("COVI-GUARD" or "STI-1499").tw,kf.	1
118	("COVI-AMG" or "sti-2020").tw,kf.	4
119	(enuzovimab or plutavimab or lomtegovimab or "HFB30132A").tw,kf.	1
120	("ABBV-47D11" or "ABBV-2B04" or "AZD7442").tw,kf.	36
121	("BI 767551" or "DZIF-10c" or "COR-101").tw,kf.	4
122	(baricitinib or olumiant or incb28050 or ly3009104).tw,kf.	1456
123	((immune adj3 (sera or serum? or plasma)) or antisera or antiserum or immun#serum).tw,kf.	79297
124	exp immunoglobulins/	994947
125	(immune* globulin? or immunoglobulin? or immunoglobulin?).tw,kf.	185483
126	((convalescent adj2 (plasma or serum or sera)) or (plasma adj3 therap*)).tw,kf.	14991
127	exp ibuprofen/	10216
128	(ibuprofen or abfen or "aches-n-pain" or "act-3" or actiprofen or "adex 200" or adex liqui-gels or advil or afebril or aktren or aktren spezial or algiasdin or algifor or algofen or algoflex or allipen or alvofen express or "am-fam 400" or anadin or anadvil or analgyl or anbifen or anco or andran or anflagen or antalgil or antarene or antiflam or apo-ibuprofen or aragel or "atril 300" or attritin or balkaprofen or berlistar or bestafen or betaprofen or bifen or bluton or brufanic or brufedol or brufen or brufort or brugesic or brumare or brumed or brupro or buburone or bufect or bufohexal or bupogesic or burana or butacortelone or butifen or caldolor or calprofen or cap-profen or cenufen or codral period pain or combiflam or contraneural or cuprofen or dalsy or "dc 7034" or "dc7034" or "dg 7034" or "dg7034" or dibufen or "diffutab sr 600" or dimidon or dolan fp or dolgit or dolobene ibu or dolocyl or dolodolgit or dolofen-f or dolomax or dolormin or dolval or donjust b or dorival or druisel or easifon or ecoprofen or emflam or epobron or ergix douleur et fievre or eudorlin extra or exidol or expanfen or febratic or febrym or femapirin or fenalgic or fenbid or flamicon or flarin or froben dolore or galprofen or gelufene or gyno-neuralgin or halprin or haltran or hemagene tailleur or h-loniten or ib-100 or ibalgin or ibofen or ibosure or ibu or ibuberl or ibucalm or ibudak or ibudol or ibudolor or ibufarmalid or ibufen or ibuflam or ibufug or ibugel or ibugesic or ibukern or ibuleve or ibulgan or ibuloid or ibumetin or ibumousse or ibunin or ibupen or ibupirac or ibuprin or ibuprocin or ibuprofene or ibuprohm or ibuprom or iburon or ibusal or ibuspray or ibustar or ibusynth or ibutop or ibux or ibuxin or idyl sr or ifenin or infant's motrin or infibu or inflanor or inflanor forte or ipren or irfen or junifen or junipro or kenfen or kontraneural or lamidon or	182252

libofem or lidifen or liptan or lopane or malafene or maxagesic or "mcn r 1451" or medicol or medipren or mediprin or mensoton or midol or momentact or motrin or mynosedin or nagifens-d or napacetin or neobrufen or neobrufen retard or nerofen or neutropain or nobfelon or nobgen or norflam-t or noritis or norton or novogent or novoprofen or nugin or nuprin or nureflex or nurofen or optifen or opturem or ostarin or ostofen or ozonol or paduden or panafen or pedea or pediacare fever or pediprofen or perdophen pediatrie or perofen or phorpain or phorpain gel or proartinal or profen or profeno or proff or proflex or proris or provin or provon or quadrax or rafen or ranofen or rapidophen or rapidophen forte or ratiadol or rebugen or renidon or reuvol or rhelafen or roidenin or rufen or rupan or saridon n or schufen or seclodin or solufen lidose or solvium or spalt or syntofene or tabalon or tab-profen or taskine or tatanal or tofen or trendar or umafen or unipro or upfen or uprofen or urem or viamal febbre e dolore or zafen or zofen).tw,kf.

129	exp Selective Serotonin Reuptake Inhibitors/	46656
130	((serotonin or 5-Hydroxytryptamine or 5-HT) adj3 (reuptake-inhibitor? or uptake-inhibitor?)) or SSRI? or fluvoxamine or du-23000 or du23000 or fluoxamin? or fluoxamine?).tw,kf.	25157
131	exp "Serotonin and Noradrenaline Reuptake Inhibitors"/	5586
132	(SNRI* or SSNRI* or (((noradrenalin or norepinephrine) adj2 serotonin) or dual) adj3 (reuptake-inhibitor* or uptake-inhibitor*)).tw,kf.	3297
133	citalopram/ or escitalopram/ or fluoxetine/ or Sertraline/	17844
134	Paroxetine/ or Desvenlafaxine Succinate/ or Duloxetine Hydrochloride/ or milnacipran/ or levomilnacipran/ or Venlafaxine Hydrochloride/	9158
135	(celexa or citalopram* or cytalopram or seropram or escitalopram* or lexapro or fluoxatin* or prozac or sarafer or altruline or sertraline or aremis or besitran or gladem or lustral or sealdin or zoloft or aropax or paroxetin* or paxil or seroxat or (desvenlafaxine* or ellefore or khedeza or o-desmethylvenlafaxine or o-norvenlafaxine or pristiq* or cymbalta or duloxetin* or dalcipran or fetzima or impulsor or ixel or jonica or levomilnacipran* or midalcipran or milnaneurax or savella* or toledomin* or dobupal or efexor or grz5rcb1qg or venlafaxin* or trevilar or vandral)).tw,kf.	33713
136	stem cell transplantation/ or hematopoietic stem cell transplantation/ or mesenchymal stem cell transplantation/ or stem-cell transplant*.tw,kf.	118748
137	Metformin/	18418
138	(metformin or anj-900 or anj900 or apophage or aron or benofomin or dabex or denkaform or deson or dextin or diabetase or diabetformin or diabetmin or diabetosan or diabex or diafat or diaformin or diaformina or diametin or diamin or dianben or diformin or diformin retard or dimefor or dimethylbiguanide or dimethyldiguanide or dmgg or dybis or efb-0027 or efb0027 or eraphage or espa-formin or euform retard or fluamine or flumamine or fornidd or fortamet or glafornil or glibudon or glifage or gliguanid or glucaminol or glucofage or glucofago or glucoform or glucoformin or glucohexal or glucoless or glucomet or glucomin or glucomine or gluconil or Glucophage* or glucostop or glucotika or gludepatic or glufor or gluformin or glukophage or glumeformin or glumet or glumetza or glupa or glustress or glyciphage or glycomet or glycon or glycoran or glyformin or glymet or haurymellin or hipoglucin or islotin or jesocrin or juformin or la-6023 or la6023 or maformin or meglucon or megan or melbin or melformin or mellittin or merckformin or mescorit or metaformin or metfogamma or metfoliquid geriasan or metforal or metformax or metformin hydrochloride or metformina or metformine or methformin or metiguanide or metomin or metphormin or miformin or neoform or newmet or nndg or reglus-500 or riomet or risidon or rudimet or siamformet or siofor or thiabet or vimetrol or walaphage).tw,kf.	29509
139	Ivermectin/	7703
140	(ivermectin or bibovel or cardomec or cevamec or diapec or driponin or efacti or epimek or equimec or eqvalan or eqvalen or iveraxiro or ivercare or ivergalen or ivergelan or ivermectina or ivermectol or iverscab or invertin or ivexterm or ivomec or k-237 or k237 or loutol or manburesa or mectizan or mk-933 or mk933 or oramec or posela or quanox	7902

	gotas or revectina or romitu or scaball or scabioral or scatol or securor or sklice or soolantra or stromectol or vona or zulima).tw,kf.	
141	Resveratrol/	11157
142	(resveratrol or srt-501 or srt501).tw,kf.	17478
143	Naltrexone/	8761
144	(naltrexone* or abernil or addex-1000 or addex1000 or adepnd or antaxon or antaxone or celupan or cyto-201 or cyto201 or depare or dependex or en-1639a or en1639a or ethylex or irt-103 or irt-104 or irt103 or irt104 or iodonal or n-cyclopropylmethylnoroxymorphone or nalerona or nalorex or naltex or naltrel or naltrexin or nemexin or nodict or nutrexon or opnt-002 or opnt002 or phaltrexia or pti-901 or pti901 or regental or revez or revia or stat-200 or stat-201 or stat-205 or stat200 or stat201 or stat205 or tranalex or trexan or um-792 or um792 or vivitrex or vivitrol).tw,kf.	8018
145	Colchicine/	15228
146	(colchicin* or colchicum-dispert or colchily or colchimedio or colchiquim or colchisol or colchysat or colcine or colcrys or colctab or colgout or colrefuz or gloperba or goutichine or goutnil or kolkicin or kolkisin or mitigare or mpc-004 or mpc004 or myinfla or tolchicine).tw,kf.	18374
147	or/24-146 [Drugs]	4512809
148	stem cell transplantation/ or hematopoietic stem cell transplantation/ or mesenchymal stem cell transplantation/ or stem-cell transplant*.tw,kf.	118748
149	Low-Level Light Therapy/ or (photobiomodulation or photo-biomodulation or photo-bio-modulation or ((low-power or low-level or low-energy or low-intensity or soft or cold) adj2 (light or laser) adj2 (therap* or irradiat*)) or (laser adj2 biostimulat*) or ILL or ((laser adj2 phototherap*) or biostimulat*)).tw,kf.	12707
150	rehabilitation/ or "activities of daily living"/ or exercise therapy/ or neurological rehabilitation/ or rehabilitation.tw,kf.	324600
151	((cognitive or neurologic*) adj4 (rehab* or motor-therap*).tw,kf.	6192
152	self-management/ or self-care/	41534
153	((patient or self) adj (manag* or treat*)) or self care).tw,kf.	98075
154	patient education as topic/ or patient medication knowledge/ or health literacy/ or (patient* adj3 (educat* or knowledg* or literacy or literate or behavior* or behaviour* or attitud* or belief* or believ*)).tw,kf.	189906
155	self-help groups/	9652
156	((self help or support*) adj3 (group? or club? or servic* or social*)) or (therap* adj3 (club? or group* or social*)).tw,kf.	152649
157	disease management/ or pain management/	84625
158	((manag* or cope or coping) adj3 (symptom* or disease* or condition* or pain or discomfort*).tw,kf.	168604
159	exercise/ or exp running/ or swimming/ or exp walking/ or exp *physical fitness/ or yoga/ or "physical education and training"/ or physical therapy specialty/	278094
160	("physical activit*" or walk* or pedestrian* or bicycl* or cycling or cyclist* or biking or bike* or "active lifestyle*" or "aerobic fitness" or "aerobic exercise*" or (running not "running water") or runner* or jog* or swim* or yoga or (physical* adj2 (activit* or active or exercise*)) or ((exercise* or fitness or aerobic*) adj2 (regimen* or training or intervention* or program* or class* or course* or train* or rehab*))).tw,kf.	603608
161	(physiotherap* or ((physical or physio) adj1 (therap* or treat*)).tw,kf.	69817

162	health services, indigenous/	4229
163	((indigenous or metis or aboriginal or inuit or (native adj (america* or alaska* or hawaii* or canad*)) or first nation* or first people*) and (healthcare or (health adj2 (care* or service* or program*)) or healing* or medic* or therap* or remed*)).tw,kf.	19801
164	exp complementary therapies/ or exp medicine, traditional/ or herbal medicine/ or plants, medicinal/	300049
165	((alternat* or complementary or folk or traditional or holistic or chinese or african or tribal) adj2 (medic* or therap* or healing* or treat* or remed*)).tw,kf.	209928
166	(hypnotism or hypnosis or hypnotherapy).tw,kf.	9901
167	(ayurved* or kampo or kanpo or acupunctur* or homeopath*).tw,kf.	41312
168	((botanical* or herb* or plant or plants or plantlet* or root or roots or natural) adj2 (drug? or extract? or healing* or ingredient? or medic* or preparation* or product or products or remedies or remedy* or supplement* or treat* or therap*)).tw,kf.	218151
169	Rest/ or (rest or (avoid* adj2 (exercise* or exert*))).tw,kf.	187955
170	exp mental health services/ or exp social work/ or psychiatric rehabilitation/ or psychiatric nursing/	137662
171	((mental health or emotion* or psych* or wellbeing or well-being or stress* or wellness* or anxiet* or depress* or obsess* or ocd or mood* or posttrauma* or post-trauma* or ptsd or schizo* or personality disorder* or bipolar* or adhd or attention deficit* or addict*) adj3 (care or service? or support? or treat* or therap* or psychotherap* or counsel* or hotline*)).tw,kf.	377613
172	(lifestyle adj3 (change* or intervention* or advice*)).tw,kf.	28194
173	exp *aftercare/ or *outpatients/	145603
174	(aftercare or after care or follow-up care or referral?).tw,kf.	160551
175	*models, organizational/ or exp *delivery of health care/	742029
176	((healthcare or health care or clinical* or public health or community) adj4 (approach* or model? or service? or deliver* or system* or distribut* or framework? or guideline?)).tw,kf.	515060
177	(recovery adj2 (team* or clinic? or centre? or center? or model* or program*)).ti,ab,kf.	4419
178	((interdisciplin* or inter-disciplin* or cross-disciplin* or multidiscipline* or multi-disciplin*) adj3 (team* or clinic? or centre? or center? or model* or program*)).ti,ab,kf.	14507
179	((care or treatment or healthcare) adj2 (model* or path* or plan*)).ti,ab,kf.	194653
180	(care adj2 (coordinat* or co-ordinat*)).ti,ab,kf.	13318
181	(patient-centred care or patient-centered care or case manag*).ti,ab,kf.	27737
182	exp "Referral and Consultation"/	87810
183	(refer* adj4 (specialist? or clinic? or therapy or therapist or counsel*)).tw,kf.	30032
184	or/148-183 [other interventions]	4078061
185	(11 or 23) and (147 or 184)	4288
186	3 or 185	4644

187	Epidemiologic studies/	9486
188	exp case control studies/	1480736
189	exp cohort studies/	2571431
190	Case control.tw.	159674
191	(cohort adj (study or studies)).tw.	340085
192	Cohort analy\$.tw.	12663
193	(Follow up adj (study or studies)).tw.	57598
194	(observational adj (study or studies)).tw.	172857
195	(prospect* adj (study or studies)).tw.	213782
196	Longitudinal.tw.	338108
197	Retrospective.tw.	790016
198	or/187-197 [Adapted from OVID observational studies filter]	3471467
199	(Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Equivalence Trial or Clinical Trial, Phase III).pt.	704265
200	exp Randomized Controlled Trial/	610088
201	exp Randomized Controlled Trials as Topic/	170776
202	Controlled Clinical Trial/	95551
203	exp Controlled Clinical Trials as Topic/	176494
204	Random Allocation/	107070
205	Double-Blind Method/	177493
206	Single-Blind Method/	33241
207	Placebos/	35934
208	Control Groups/	2087
209	(random* or sham or placebo*).ti,ab,hw,kf,kw.	1878649
210	((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf.	273138
211	((tripl* or trebl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf.	1766
212	(control* adj3 (study or studies or trial* or group*)).ti,ab,kf.	1275703
213	(Nonrandom* or non random* or non-random* or quasi-random* or quasirandom*).ti,ab,hw,kf.	56985
214	allocated.ti,ab,hw.	87490
215	((open label or open-label) adj5 (study or studies or trial*)).ti,ab,hw,kf.	46907
216	((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).ti,ab,hw,kf.	12991

217	(pragmatic study or pragmatic studies).ti,ab,hw,kf,kw.	638
218	((pragmatic or practical) adj3 trial*).ti,ab,hw,kf.	8171
219	((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).ti,ab,hw,kf.	13277
220	(phase adj3 (III or "3") adj3 (study or studies or trial*)).ti,hw,kf.	36306
221	or/199-220 [Adapted from "Strings attached: CADTH database search filters"]	2691325
222	186 and (198 or 221)	1569
223	case reports/ or (case-stud* or case-report*).jw. or (case* and report*).ti.	2511796
224	(address or autobiography or bibliography or biography or case reports or classical article or clinical trial, veterinary or clinical trials, veterinary as topic or editorial or historical article or interview or news or newspaper article or observational study, veterinary).pt.	3706107
225	222 not (223 or 224)	1524
226	limit 225 to yr="2022 - 2024"	1239
227	(202205* or 202206* or 202207* or 202208* or 202209* or 20221* or 2023* or 2024*).ez,dt,ed.	3064509
228	226 and 227	1103

Table S8. Search from Embase [Ovid]

Embase <1974 to 2024 February 09>

1	long COVID/dm, dt, th, pc	556
2	((post covid* or post coronavirus* or long covid* or long coronavirus*) adj2 (prevent* or prophyla* or treatment* or management)).ab.	413
3	1 or 2	904
4	Long covid/	6847
5	(long COVID* or long coronavirus* or longCOVID* or longcoronavirus*).ti,ab,kf.	5869
6	(sequela* adj5 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV2 or SARSCOV-2 or SARSCOV2)).ti,ab,kf.	3508
7	((post or chronic or long term or longterm) adj3 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV2 or SARSCOV-2 or SARSCOV2) adj4 (condition* or sequela* or syndrome* or subsyndrome* or clinical syndrome* or disorder* or symptom* or outcome* or clinical outcome* or function* or followup or follow-up or subtyp* or sub-typ* or phenotyp* or complication* or survivor*).ti,ab,kf.	6440
8	((post acute or postacute or late complication*) adj3 (COVID* or coronavirus* or corona virus* or SARS-COV-2 or SARS-COV2 or SARSCOV-2 or SARSCOV2)).ti,ab,kf.	2357
9	PASC.ti,kf.	430
10	post-COVID*.kf.	1855

11	(post-COVID* adj fatigue).ti,ab,kf.	45
12	or/4-11	14166
13	exp Coronavirus disease 2019/	383874
14	exp Severe acute respiratory syndrome coronavirus 2/	109044
15	(COVID* or coronavirus* or corona virus* or 2019nCoV or 19nCoV or COVID19* or COVID or SARS-CoV-2 or SARSCOV-2 or SARS-CoV2 or SARSCOV2 or SARS coronavirus 2 or Severe Acute Respiratory Syndrome Coronavirus 2 or Severe Acute Respiratory Syndrome Corona Virus 2).ti,ab,kf,ot.	477967
16	or/13-15	511459
17	((post acute or postacute or sub-acute or subacute or chronic or long or longterm or late) adj sequela*) or PASC).ti,ab,kf.	5046
18	(long haul* or longhaul*).ti,ab,kf.	1567
19	((persist* or long* or residual or prolonged) adj8 ((olfactory or chemosensor*) adj (disorder* or dysfunction*)).ti,ab,kf.	274
20	(post* or chronic* or long or longterm or sequela*).ti,ab,kf.	7967312
21	(PFS or (pulmonary adj3 fibro*) or (lung adj3 fibro*) or fatigue syndrome? or myalgic encephalomyelitis or ME-CFS or ME?CFS or (postural adj3 tachycardia*) or POTS or MIS-C or MIS-A or PIMS or PIMSTS or PIMS-TS).ti,ab,kf.	203855
22	((multisystem* or multi-system*) adj3 (inflamm* or hyperinflamm*).ti,ab,kf.	6458
23	20 and (21 or 22)	67969
24	or/17-19,23	74504
25	16 and 24	5051
26	exp *vitamin/	301224
27	exp *folic acid/	22253
28	*dietary supplement/	7882
29	vitamin?.tw,kf.	326137
30	riboflavin.tw,kf.	12729
31	(niacinamide or enduramide or nicobion or nicotinamide or papulex).tw,kf.	29463
32	(thiamine or aneurin or thiamin).tw,kf.	14859
33	(folic acid or folacin or folate or folvite or pteroylglutamic acid).tw,kf.	62402
34	(ascorbic acid or ferrous ascorbate or hybrin or "l-ascorbic acid" or magnesium ascorbate or magnesium ascorbicum or "magnesium di-l-ascorbate" or magnorbin or sodium ascorbate).tw,kf.	43636
35	((diet* or nutrition* or herbal* or food?) adj3 supplement*).tw,kf.	100263
36	exp probiotic agent/	55741
37	exp probiotic agent/ or probiotic*.tw,kf.	66494

38	Zinc/ or Magnesium/ or Selenium/ or selenium*.tw,kf.	262159
39	(mineral* or zinc or magnesium).tw,kf.	503713
40	Ubiquinone/ or "coenzyme q10".tw,kf.	14205
41	exp *antiinflammatory agent/	861548
42	((antiinflammat* or anti inflammator*) adj2 (drug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)) or NSAID or NSAIDs).tw,kf.	119071
43	exp *corticosteroid/	318495
44	(adrenal cortex hormone? or corticoid? or cortical steroid? or cortico steroid? or corticosteroid? or dermocorticosteroid?).tw,kf.	201481
45	(dexamethasone? or decaject? or decameth? or decaspray? of dexasone? or dexpak? or hexadecadrol? or hexadrol? or maxidex? or methylfluorprednisolone? or millicorten? or oradexon?).tw,kf.	96721
46	(prednisone or cortan or cortancyl or cutason or dacortin or decortin or decortisyl or dehydrocortisone or deltasone or encorton or encortone or enkortolon or kortancyl or liquid pred or meticorten or orasone or panafcort or panasol or predni tablinen or prednidib or predniment or prednison acsis or prednison galen or prednison hexal or pronisone or rectodelt or sone or sterapred or ultracorten or winpred or delta cortisone).tw,kf.	63181
47	(methylprednisolone or methylprednisolone or medrol or metipred or urbason).tw,kf.	37613
48	(hydrocortisone or "acticort" or "aeroseb hc" or "ala-cort" or "ala-scalp" or "alfacort" or "algicortis" or "alkindi" or "alpha derm" or "alphaderm" or "anucort-hc" or "anumed-hc" or "anutone-hc" or "aquanil hc" or "balneol-hc" or "barseb hc" or "beta-hc" or "biacort" or "cetacort" or "cobadex" or "colocort" or "compound f" or "cordicare lotion" or "coripen" or "cort dome" or "cortef" or "cortef cream" or "cortenema" or "cortibel" or "corticorenol" or "cortifan" or "cortiphate" or "cortisol" or "cortisole" or "cortispray" or "cortoderm" or "cortril" or "cotacort" or "covocort" or "cremicort-h" or "cutaderm" or "dermacrin hc lotion" or "dermaid" or "derm-aid cream" or "dermaid soft cream" or "dermocare" or "dermcortal" or "dermolate" or "dioderm" or "eczacort" or "ef cortelan" or "efcortelan" or "egocort" or "egocort cream" or "eksalb" or "eldecort" or "emo-cort" or "epicort" or "ficortril" or "filocot" or "flexicort" or "glycort" or "gly-cort" or "hc no. 1" or "hc no. 4" or "h-cort" or "hebcort" or "hebcort v" or "hemorrhoidal hc" or "hemril-30" or "hemril-hc uniserts" or "hi-cor" or "hidrotisona" or "hycor" or "hycort" or "hydracort" or "hydrasson" or "hydro ricortex" or "hydrocort" or "hydrocorticosteroid" or "hydrocortisate" or "hydrocortison" or "hydrocortisonum" or "hydrocortisy" or "hydrocortone" or "hydrogalen" or "hydrokort" or "hydrokortison" or "hydro-rx" or "hydrotopic" or "hysone" or "hytisone" or "hytone" or "hytone lotion" or "incortin h" or "instacort 10" or "kyppakkaus" or "lacticare hc" or "lemnis fatty cream hc" or "lenirit" or "medihaler cort" or "medihaler duo" or "medrocil" or "mildison" or "mitocortyl demangeaisons" or "munitren" or "nogenic hc" or "novohydrocort" or "nsc 10483" or "nsc 741" or "nsc10483" or "nutracort" or "optef" or "otosone f" or "penecort" or "plendren" or "prepcont" or "prevex hc" or "pro cort" or "procort" or "proctocort" or "proctosert hc" or "proctosol-hc" or "proctosone" or "proctozone hc" or "procutan" or "rectasol-hc" or "rectocort" or "rederm" or "sanatison" or "scalp-aid" or "schericur" or "schericur 0.25%" or "scherosone f" or "sistral hydrocort" or "skincalm" or "stie-cort" or "substance m" or "synacort" or "texacort" or "triburon-hc" or "unicort" or "vasocort").tw,kf.	112716
49	(nitric oxide or endogenous nitrate vasodilator or mononitrogen monoxide or nitrogen monoxide or genosyl or inomax or noxivent).tw,kf.	215893
50	(prednisolone or "adelcort" or "antisolon" or "antisolone" or "aprednislone" or "aprednislone" or "benisolone" or "benisolone" or "berisolone" or "berisolone" or "caberdelta" or "capsoid" or "codelcortone" or "co-hydeltra" or "compresolon" or "cortadeltona" or "cortadeltona" or "cortalone" or "cortelinter" or "cortisolone" or "cotolone" or "dacortin" or "dacortin h" or "dacratin" or "decaprednil" or "decortin h" or "decortril" or "dehydro cortex" or "dehydro hydrocortison" or "dehydro hydrocortisone" or "dehydrocortex" or "dehydrocortisol" or "dehydrocortisole" or "dehydrohydrocortison" or "dehydrohydrocortisone" or "delcortol" or "delta 1 hydrocortisone" or "delta cortef" or "delta cortril" or "delta ef cortelan" or "delta f" or "delta hycortol" or "delta hydrocortison" or "delta hydrocortisone" or	49769

"delta ophticor" or "delta stab" or "delta1 dehydrocortisol" or "delta1 dehydrohydrocortisone" or "delta1 hydrocortisone" or "deltacortef" or "deltacortenolo" or "deltacortil" or "deltacortoil" or "deltacortril" or "deltaderm" or "deltaglycortril" or "deltahycortol" or "deltahydrocortison" or "deltahydrocortisone" or "deltaopticor" or "deltasolone" or "deltastab" or "deltidrosol" or "deltisilone" or "deltisolon" or "deltisolone" or "deltolasson" or "deltolassone" or "deltosona" or "deltosone" or "depo-predate" or "dermosolon" or "dhasolone" or "di adreson f" or "di adresone f" or "diadreson f" or "diadresone f" or "dicortol" or "domucortone" or "encortelon" or "encortelone" or "encortolon" or "equisolon" or "fernisolone-p" or "glistelone" or "hefasolon" or "hostacortin h" or "hostacortin h vet" or "hydeltra" or "hydeltrone" or "hydrelta" or "hydrocortancyl" or "hydrocortidel" or "hydrodeltalone" or "hydrodeltisone" or "hydroretrocortin" or "hydroretrocortine" or "inflanefran" or "insolone" or "keteocort h" or "keypred" or "lenisolone" or "leocortol" or "liquipred" or "lygal koftinktur n" or "mediasolone" or "meprisolone" or "meprisolone" or "metacortalon" or "metacortalone" or "metacortandralon" or "metacortandralone" or "metacortelone" or "meti derm" or "meticortelone" or "metiderm" or "morlone" or "mydrapred" or "neo delta" or "nisolon" or "nisolone" or "nsc 9120" or "nsc9120" or "opredsone" or "panafcortelone" or "panafcortolone" or "panafort" or "paracortol" or "phlogex" or "pre cortisy" or "preconin" or "precortalon" or "precortancyl" or "precortisy" or "predacort 50" or "predaject-50" or "predalone 50" or "predartrina" or "predartrine" or "predate-50" or "predeltilone" or "predisole" or "predisyr" or "pred-ject-50" or "predne dome" or "prednecort" or "prednedome" or "prednelan" or "predni coelin" or "predni h tablinen" or "prednicoelin" or "prednicort" or "prednicortelone" or "prednifor drops" or "predni-helvacort" or "predniment" or "predniretard" or "prednis" or "prednisil" or "prednisolone" or "prednisolona" or "prednisolone alcohol" or "prednisolone h" or "prednisolone oleosae sr 82" or "prednivet" or "prednorsolon" or "prednorsolone" or "predonine" or "predorgasolona" or "predorgasolone" or "prelon" or "prelon" or "prenilone" or "prenin" or "prenolone" or "preventan" or "prezolon" or "rubycort" or "scherisolon" or "scherisolona" or "serilone" or "solondo" or "solone" or "solupren" or "soluprene" or "spiricot" or "spolotane" or "sterane" or "sterolone" or "supercortisol" or "supercortizol" or "taracortelone" or "walesolone" or "wysolone").tw,kf.

- | | | |
|----|---|--------|
| 51 | (aspirin or acetylsalicylic acid or "8-hour bayer" or "acenterine" or "acesal" or "acetan" or "acetard" or "acetilic" or "acetyl" or "acetilum" or "acetonyl" or "acetophen" or "acetosal" or "acetosalicylic acid" or "acetosalin" or "acetosalum" or "acetyl salicylate" or "acetyl salicylic acid" or "acetylic salicylic acid" or "acetylin" or "acetylo" or "acetylo salicylic acid" or "acetylon" or "acetylosalicylic acid" or "acetylsa" or "acetylsalicyclic acid" or "acetylsalicyl" or "acetylsalicylate" or "acetylsalicylate strontium" or "acetylsalicylic acid plus glycine" or "acetylsalicylic acid sodium salt" or "acetylsalicylic acid strontium salt" or "acetylsalycic acid" or "acetylsalycic acid" or "acetsal" or "acidulatum" or "acidum acetyl salicylicum" or "acidum acetylosalicylicum" or "acidum acetylsalicylicum" or "actorin" or "acylpryn" or "acylpryne" or "acytosal" or "adiro" or "alabukun" or "alasil" or "albyl e" or "albyl minor" or "alka seltzer" or "alkaspirin" or "anasprin" or "andol" or "anopyrin" or "ansin" or "anthrom" or "aptor" or "arthralgyl" or "arthritis strength bufferin" or "asacard" or "asaetta" or "asaflow" or "asaphen" or "asapor" or "asatard" or "asawin" or "aspec" or "aspent" or "aspergum" or "aspex" or "aspilets" or "aspirem" or "aspirgran" or "aspiricor" or "aspirina" or "aspirine" or "aspirinine" or "aspirisucre" or "aspisoli" or "aspoc cid" or "aspro" or "aspro cardio" or "aspro clear" or "asproflash" or "asrina" or "asrivo" or "asta" or "astic" or "astic acid" or "astrix" or "bamyl" or "bayaspirina" or "bebesan" or "biprin" or "bokey" or "boxazin" or "breoprin" or "bufferin" or "cafenol" or "cardioasa" or "cardiosae" or "cardioaspirina" or "cartia" or "caspirin" or "catalgine" or "catalgix" or "cemerit" or "cemirit" or "claradin" or "claragine" or "colfarit" or "comoprin" or "contrheuma" or "contrheuma retard" or "darosal" or "depot aspirin" or "dispirin" or "dolean" or "durlaza" or "dusil" or "easprin" or "ecasil" or "ecosprin" or "ecotrin" or "egalgic" or "emocin" or "empirin" or "encaprin" or "encine em" or "endosprin" or "entaprin" or "entericin" or "enteroprin" or "enterosarine" or "enterospirine" or "entrophen" or "eskotrin" or "euthermine" or "extren" or "flamasacard" or "genasprin" or "globentyl" or "godamed" or "gotosan" or "helicon" or "herz ass" or "hjertemagnyl" or "idotyl" or "infatabs a" or "istopirin" or "istopyrine" or "ivepirine" or "juvepirine" or "keypo" or "kilios" or "kinderaspirin" or "magnecyl brus" or "magnyl dak" or "mcn r 358" or "measurin" or "mejoral" or "melabon" or "micristin" or "micropyrin" or "migrasaa" or "mikristin" or "miniasal" or "mycristin" or "naspro" or "novasen" or "nu seal" or "nuseals" or "nu-seals" or "nu-seals asa" or "ortho acetoxybenzoate" or "ortho acetoxybenzoic acid" or "ortho acetyloxybenzoate" or "ortho acetyloxybenzoic acid" or "ostoprin" or "pancemol" or "para acetylsalicylic acid" or "paracin" or "paynocil" or "pengo" or "platet 300 cleartab" or "plewin" or "polopiryna" or "premaspin" or "primaspan" or "proprin" or "pyronoval" or "reumyl" or "rhodine" or "rhonal" or "ronal" or "salacetin" or "salacetogen" or "saletin" or "salisalido" or "salospir" or "sargepirine" or "sedergine" or "sedergine forte" or "sodium acetylsalicylate" or "sodium bicarbonate acetyl salicylate" or "sodium bicarbonate acetylsalicylate" or "soldral" or "solpyron" or "solucetyl" or "solupsa" or "spren" or "super tru" | 147604 |
|----|---|--------|

	or "tapal" or "temagin" or "tevapirin" or "th 2152" or "thrombo-aspilets" or "toldex retard" or "treupahlin" or "treuphalin" or "tromalyt" or "tromcor" or "turivital" or "vazalore" or "verin" or "vitalink" or "xaxa" or "zorprin").tw,kf.	
52	(adalimumab or "abp 501" or "abp501" or "abrilada" or "abt d2e7" or "abtd2e7" or "adaly" or "amgevita" or "amjevita" or "amsparity" or "avt 02" or "avt02" or "bat 1406" or "bat1406" or "bax 2923" or "bax 923" or "bax2923" or "bax923" or "bi 695501" or "bi695501" or "chs 1420" or "chs1420" or "cinnora" or "ct p17" or "ctp17" or "cyltezo" or "da 3113" or "da3113" or "dmb 3113" or "dmb3113" or "exemptia" or "fkb 327" or "fkb327" or "fyzoclad" or "gp 2017" or "gp2017" or "hadlima" or "halimatoz" or "hefiya" or "hlx 03" or "hlx03" or "hulio" or "humira" or "hyrimoz" or "ibi 303" or "ibi303" or "idacio" or "imraldi" or "kromeya" or "lu 200134" or "lu200134" or "m 923" or "m923" or "mabura" or "monoclonal antibody d2e7" or "msb 11022" or "msb11022" or "ons 3010" or "ons3010" or "pf 06410293" or "pf 6410293" or "pf06410293" or "pf6410293" or "raheara" or "sb 5" or "sb5" or "solymbic" or "trudexa" or "zrc 3197" or "zrc3197").tw,kf.	28009
53	(celecoxib or "aclarex" or "artilog" or "artroxil" or "caditar" or "celcox" or "celebra" or "celebreks" or "celebrex" or "celecox" or "celib" or "celora" or "coxe" or "coxit" or "dilox" or "eliflam" or "elyxyb" or "lexfin" or "onsenal" or "sc 58635" or "sc58635" or "solexa" or "ym 177" or "ym177" or "zycel").tw,kf.	14009
54	(diclofenac or "abdiflam" or "abitren" or "acuflam" or "akis" or "algipatch" or "algistick" or "algopain eze" or "algoplast" or "allvoran" or "almiral" or "alonpin" or "antalcalm" or "apo-diclofenac ec" or "arcanafenac" or "arthrifen" or "artren" or "artrenac" or "artrites" or "assaren" or "athrofen" or "ba 47210" or "ba47210" or "berafen gel" or "berifen" or "betaren" or "bolabomin" or "calozan" or "catanac" or "catas" or "cencenag" or "clo-far" or "clofec" or "clofen" or "clonac" or "clonaren" or "clonodifen" or "cordralan" or "curinflam" or "ddl plaster" or "declophen" or "decrol" or "deflamat" or "deflam-k" or "delphinac" or "denaclof" or "depain" or "diceus" or "dicipan" or "diclac" or "diclax" or "diclo" or "diclobasan" or "diclobene" or "diclod" or "dicloden" or "diclodoc" or "diclodolor" or "diclofen" or "diclofen cremogel" or "diclofenac rekur" or "diclofenac resin" or "diclofenac resinate" or "diclofenac sodium" or "dicloflam" or "diclohexal" or "dicloin" or "diclomax" or "diclomol" or "diclon" or "diclopax" or "diclophenac sodium" or "diclopuren" or "dicloral" or "dicloran gel" or "diclorecip" or "dicloren" or "dicloremum" or "diclosan sr" or "diclosian" or "diclotec" or "diclowal" or "dicsnal" or "difen" or "difena" or "difenac" or "difenol gel" or "difnal k" or "dioxaflex" or "dioxaflex retard" or "divoltar" or "dixol" or "doflastad" or "doflex" or "dolaren" or "dolflam-retard" or "dolo voltaren" or "doloflam" or "dolotren" or "doragon" or "dosanac" or "duravolten" or "dycon sr" or "dyloject" or "ecofenac" or "econac" or "effekton" or "eflagen" or "epifenac" or "eslofen" or "evadol" or "evinopon" or "feloran" or "fenac" or "fenadium" or "fenaspec" or "flameril" or "flexagen" or "flogofenac" or "flogosin d" or "flogozan" or "fortfen sr" or "freejex" or "gp 45840" or "grofenac" or "hizemin" or "imflac" or "inac gel" or "indicam" or "inflamac" or "inflanac" or "isv 205" or "isv205" or "jonac gel" or "kadiflam" or "kinespir" or "klofen l" or "klotaren" or "kriplex" or "lesflam" or "leviogel" or "lifenac" or "lofenac" or "lotirac" or "magluphen" or "merflam" or "modifенac" or "monoflam" or "motifene" or "naboal" or "nac gel" or "naclof" or "nacoflar" or "nadifen" or "novapirina" or "novo-difenac" or "novolten" or "ofenac" or "olfen" or "optanac" or "orthophen" or "osteoflam" or "paintstop" or "panamor" or "pennsaid" or "profenac" or "relaxyl gel" or "remethan" or "renvol emulgel" or "rewodina" or "rheufenac" or "rheumafen" or "rheumatac" or "rheumatac retard" or "rhewlin" or "rhewlin sr" or "rhumalgan" or "rolactin" or "sailib" or "savism" or "sefnac" or "slofenac" or "sodium diclofenac" or "solaraze" or "sophenoderm" or "soproxen" or "spraymik" or "sr 318t" or "staren" or "sting gel" or "tabiflex" or "tds 943" or "tds943" or "tigen plaster" or "toraren" or "traulen" or "tsudohmin" or "uniclonax" or "uniren" or "valentac" or "vartelon" or "veral" or "voldal" or "voldic" or "volero" or "volfenac" or "volna-k" or "volsaid" or "volta" or "voltadex emulgel" or "voltadvance" or "voltalen" or "voltalen emulgel" or "voltalgan" or "voltaren" or "voltarene" or "voltarenspe" or "voltarol" or "voltine" or "voltral" or "voltrix" or "voren emulgel" or "votalen" or "vooveran" or "vurdon" or "wergyl" or "xenid" or "yuren" or "zolterol" or "zorvolex").tw,kf.	24901
55	(dimethyl sulfoxide or "damul" or "demasorb" or "demavet" or "demeso" or "demexide" or "dimethyl sulphoxide" or "dimethylsulfoxide" or "dimethylsulphoxide" or "dimexide" or "dms 70" or "dms 90" or "dms70" or "dms90" or "dms0" or "dolicur" or "domoso" or "dromisol" or "gamasal 90" or "hyadur" or "infiltrina" or "methyl sulfoxide" or "methylsulfoxide" or "nsc 763" or "nsc763" or "rimso 100" or "rimso 50" or "somipront" or "sq 9453" or "sq9453" or "syntexan").tw,kf.	46043
56	(indometacin or "algiflam" or "algometacin" or "amuno" or "antalgic dialicels" or "apo-indometacin" or "areumatin" or "argilex" or "arthrexin" or "articulen" or "artracin" or "artrilona s" or "artrinovo" or "artrocid" or "asimet" or	47351

"benocid" or "betacin" or "bonidon" or "bouycin" or "catlep" or "chrono indocid" or "chronoindocid" or "confortid" or "docin" or "dolazal" or "dolazol" or "dolcidium" or "dometin" or "durametacin" or "elmego spray" or "elmetacin" or "endometacin" or "flamaret" or "flexin continuo" or "grindocin" or "helvecin" or "idicin" or "im-75" or "imbrilon" or "imet" or "inacid" or "indacin" or "indalgin" or "inderapollon" or "indicin" or "indo phlogont" or "indocap" or "indocid" or "indocin" or "indocolir" or "indocollyre" or "indogesic" or "indolag" or "indolar sr" or "indolemon" or "indolemon" or "indomecin" or "indomed" or "indomee" or "indomelan" or "indomelol" or "indomet retard" or "indometacin sodium" or "indometacine" or "indomethacin" or "indomethacine" or "indomethacinum" or "indomethegan" or "indometicina mckesson" or "indometin" or "indometin depot" or "indomexum" or "indomin" or "indono" or "indoptic" or "indoptol" or "indorektal" or "indorem" or "indos" or "indosan" or "indosima" or "indosmos" or "indo-tablinen" or "indotard" or "indovis" or "indoxen" or "indoy" or "indren" or "indrenin" or "indylon" or "inflazon" or "inmetsin" or "inteban" or "lauzit" or "luiflex" or "lyo indometacin trihydrate" or "malival" or "mcn r 1166" or "mcn r1166" or "metacen" or "methacin" or "methindol" or "methindole" or "methocaps" or "metindol" or "mezolin" or "miometacen" or "mk 615" or "mk615" or "mobilan" or "novomethacin" or "osmogit" or "osmosin" or "reumacid" or "reusin" or "rheumacid" or "rheumacin" or "salinac" or "servimeta" or "sidocin" or "tannex" or "taye" or "tivorbex" or "vi-gel" or "vonus").tw,kf.

57	(methotrexate or "abitrexate" or "amethopterin" or "amethopterine" or "ametofolan" or "biotrexate" or "canceren" or "cl 14377" or "cl14377" or "emtexate" or "emthexat" or "emthexate" or "enthexate" or "farmitrexat" or "farmitrexate" or "farmotrex" or "folex" or "ifamet" or "imeth" or "intradose mtx" or "jylamvo" or "lantarel" or "ledertrexate" or "maxtrex" or "metex" or "methoblastin" or "methohexate" or "methotrate" or "methotrexat" or "methotrexato" or "methotrexate" or "methotrexate" or "methylaminopterin" or "methylaminopterine" or "meticil" or "metoject" or "metothrexate" or "metotrexat" or "metotrexate" or "metotrexin" or "metrex" or "mexate" or "mpi 5004" or "mpi5004" or "neotrexate" or "nordimet" or "novatrex" or "nsc 740" or "nsc740" or "otrexup" or "otrexup pfs" or "rasuovo" or "reditrex" or "reumatrex" or "rheumatrex" or "texate" or "texorate" or "trexall" or "xaken" or "xatmep" or "zexate").tw,kf.	84549
58	(naproxen or "acusprain" or "aflamax" or "aflaxen" or "agilex" or "agilken" or "aleve" or "alpoxen" or "alpron" or "anaprox" or "anexopen" or "apo-naproxen" or "apranax" or "apraxin" or "apronax" or "artagen" or "artron" or "artroxen" or "axer alfa" or "babel" or "bipronyl" or "bonyl" or "congex" or "crysanal" or "dafloxa" or "daprox" or "daprox enter" or "deflamox" or "dextro naproxen" or "diferbest" or "diocodal" or "dolormin fuer Frauen" or "dolormin fuer Frauen" or "dolormin gs" or "dysmenalgit" or "dysmenalgit n" or "ec naprosyn" or "equiproxen" or "femex" or "feminax ultra" or "flanax" or "flanax forte" or "floginax" or "flonax" or "floxene" or "fuxen" or "galpharm period pain relief" or "gibixen" or "headlon" or "iraxen" or "laraflex" or "lasonil antinfiammatorio e antireumatico" or "lefaine" or "leniartil" or "levo naproxen" or "licorax" or "methoxypropiocin" or "miranax" or "momendol" or "nafasol" or "naixan" or "napolon" or "naposin" or "napreben" or "naprelan" or "napren" or "naprium" or "naprius" or "naproflam" or "naprogesic" or "naprong" or "naprontag" or "naproxen" or "naprossene" or "naprostad" or "naprosyn" or "naprosyne" or "naprovite" or "naproxeno" or "naproxi 250" or "naproxi 500" or "naproxyn" or "naprozyne" or "naprux" or "napsyn" or "napxen" or "narma" or "narocin" or "naxen" or "naxopren" or "naxyn" or "neprossin" or "norswel" or "novonaprox" or "novo-naprox" or "novuran" or "nuprafem" or "nycopren" or "pactens" or "prexan" or "priaxen" or "prodil" or "pronaxen" or "proxen" or "proxidol" or "rahsen" or "rs 3540" or "rs 3650" or "rs3540" or "rs3650" or "sanomed" or "saritilron" or "seladin" or "shiprosyn" or "sutolin" or "synaprosyn" or "synflex" or "tohexen" or "uniflam" or "u-ritis" or "velsay" or "veradol" or "vinsen" or "wintrex" or "xenar" or "xenobid").tw,kf.	12424
59	*hydroxychloroquine/	6890
60	(hydroxychloroquine or chloroquinol or ercoquin or hydrochloroquine or hydrochloroquine or oxychloroquine or quensyl or sn-8137 or sn8137 or tlc-19 or tlc19 or win-1258 or win1258).tw,kf.	16569
61	exp *histamine H1 receptor antagonist/ or exp *histamine H2 receptor antagonist/ or antihistamine*.tw,kf.	127161
62	exp *antivirus agent/	493849
63	((antivir* or anti vir*) adj2 (drug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)).tw,kf.	37696
64	*tocilizumab/	5743

65	(tocilizumab or actemra or atlizumab or lusinex or "r 1569" or r1569 or roactemra).tw,kf.	15060
66	*baricitinib/	1473
67	(baricitinib or "incb 028050" or "incb 28050" or incb028050 or incb28050 or "ly 3009104" or ly300910 or olumiant).tw,kf.	2931
68	*remdesivir/	1598
69	(remdesivir or redyx or ro-7286260 or ro7286260 or veklury or gs-5734 or gs5734).tw,kf.	5444
70	*nirmatrelvir plus ritonavir/	592
71	(nirmatrelvir* or pf-07321332 or pf-7321332 or pf07321332 or pf7321332 or paxlovid or ritonavir* or a-84538 or a84538 or abt-538 or abt-84538 or abt538 or abt84538 or norvir or orb-102 or orb102 or ritovir).tw,kf.	14643
72	*favipiravir/	700
73	(favipiravir or avicod or avigan or favicovir or t-705 or t705).tw,kf.	1955
74	*oseltamivir/	2733
75	(oseltamivir or ebilfumin or en-241104 or en241104 or enzamir or fluvir or gs-4104 or gs4104 or gs4104002 or hgp-0919 or hgp0919 or hip-1403 or hip1403 or oseltamavir or ro-64-0796 or ro640796 or segosana or tamiflu or tamivil).tw,kf.	7838
76	*ganciclovir/	5489
77	(ganciclovir or gancyclovir or citovirax or cymeven or cymeven* or cytovene or denocin or denosine or dihydroxypropoxymethylguanine or virgan or vitrasert or zirgan).tw,kf.	12021
78	((anticoagulant* or anti coagulant* or antithrombo* or anti-thrombo*) adj2 (drug? or pharmaceutical? or agent? or substance? or medicin* or prescription?)).tw,kf.	17118
79	exp *low molecular weight heparin/	17585
80	(low adj3 heparin).tw,kf.	24892
81	(choay or depolymerized heparin or traxyparine).tw,kf.	371
82	(enoxaparin or clexan or clexane or decipar or inhixa or klexane or ledraxen or lovenox or neoparin or qualiop klinik or thorinane).tw,kf.	13954
83	*azithromycin/	7976
84	(azithromycin or aratro or aruzilina or atizor or azacid or azadose or azasite or azatril or azenil or azi-sandoz or azi-teva or azibactron or azibiot or azimed or azimin or azimycin or aziprome or azirox or azirute or azithral or azithran or azitredil or azitrocin or azitromax or azitromicin* or azitrox or azivirus or aziwill or aziwok or azomyne or azromax or aztrin or azycyna or azycop or azylung or azytact or azyter or azithromycin or bactrazol or batif or bazy or bezanin or ciroz or clamelle or goldamycin or inedol or infectoazit or kromicin or macromax or macrozit or makromicin or mezatin or nobaxin or novozithron or octavax or ordipha or razimax or rezan or ribotrex or sumamed or sunamed or tobyl or tromix or trozamil or trozocina or ultreon or vinzam or xithrone or zaraxin or zaret or zarom or zedbac or zetamax or zeto or zibramax or zifin or zimacrol or zimericina or zinfect or zistic or zithrobest or Zithromax* or zithroplus or zithrotel or zithrox or zithroxyn or zitinn or zitrim or zitrobifan or zitrobiotic or zitrocin* or zitrogram or zitronova or zitrozin or zmax).tw,kf.	20775
85	*doxycycline/	12381

86	(Doxycycline or adoxa or amermycin or apprilon or atrax or azodoxat or bactidox or banndoclin or basedillin or bassado or biocolyn or biodoxi or bronmycin or calcium-doxycycline or cloran or cyclidox or dentistar or deoxycycline or deoxymycin dispersal or deoxymykojin or deoxyoxtetracycline or desoxy oxytetracycline or desoxycycline or doinmycin or dosil or dotur or doxaciclinodoxat or doxatet or doxi-sergo or doxibiotic or doxycycline or doxilin or doximed or doximycin or doxin or doxine or doxirobe or doxycycline or doxsig or doxy or doxybiocin or doxygen or doxygen retard or doxychel or doxycin or doxycyclin or doxylag or doxylin or doxymycin or doxypuren or doxytec or doxytrim or dumoxin or duracycline or efracea or esdoxin or etidoxina or gewacyclin or ibradene or idocyclin or idocyklin or interdoxin or investin or longamycin or lydox or magdrin or medomycin or mespafin or mildox or miraclin or monodox or nanodox or nordox or nsc-56228 or oracea or oraycea or paldomyuin or radox or remycin or respidox or roximycin or serodoxy or servidoxine or servidoxyne or siadocin or siclidon or sigadoxin or spanor or supracyclin or supramycin or tenutan or tolexine or torymycin or tsurupioxin or unidox or veemycin or viadoxin or vibra-s or vibrabiotic or vibracina or vibradox or vibramicina or vibramycin* or vibraveneuse or vibravenos or vibravet or viradoxyl-n or wanmycin or xyrosa or zadorin or zenavod).tw,kf.	28088
87	exp *amoxicillin/	16305
88	(actimoxi* or amoxicillin* or amoxil or amoxyccillin* or clamoxyl or hydroxyampicillin or penamox or polymox or trimox or wymox or amox-clav or amoxi-clavulanate or augmentin or clavulin or co-amoxiclav or spektramox or synulox).tw,kf.	39349
89	*cotrimoxazole/	17216
90	*vancomycin/	21867
91	(abactrim or bactifor or bactrim or biseptol or centran or centrin or co-trimoxazole or drylin or eselectin or eusaprim or insozalin or kepinol or lescot or metomide or oriprim or septra or septrin or (sulfamethoxazole adj2 trimethoprim) or sulprim or sumetrolim or trimedin or trimethoprim-sulfa or trimezole or trimosulfa or (diatracin or vanco-cell or vanco azupharma or vanco-saar or vancocin* or vancomicina* or vancomycin*)).tw,kf.	76390
92	*ceftriaxone/ or exp *cephalosporin derivative/ or exp *quinolone derivative/	119906
93	(acantex or axone or benaxona or biotrakson or biotriax or bioxon or broadced or brospec or cef-3 or cefaflox or cefalogen or cefatriaxone or cefaxona or cefaxone or cefin or cefotal or cefotriaxon or cefotriaxone or cefriex or ceftrex or ceftrian or ceftriaxone or ceftrilem or cefxon or cephin or cephtriaxone or cerixon or cikedrix or ecotrixon or elpicef or eurocef or ferfacef or forgram or glicocef or gomcephin or grifotriaxona or incephin or keftriaxon or keptrix or lopratin or lyceft or medoxonum or megin or mesporin or monocef or nakaxone or novosef or oframax or pantrixon or retrokor or rinxofay or rocefalin or rocefain or rocephalin or Rocephin* or rocida or rowcef or roxcef or roxon or samixon or sintrex or socef or sunflow or tacex or torocef-1 or trexofin or triaken or triax or triaxone or tricefin or tricephelin or trijec or xtenda or zefaxone or zefone 250).tw,kf.	24945
94	(Fluoroquinolone* or Ciprofloxacin* or Fleroxacin* or Enoxacin* or Enrofloxacin* or Gatifloxacin* or Gemifloxacin* or Moxifloxacin* or Norfloxacin* or Ofloxacin* or Levofloxacin* or Pefloxacin* or (Cephalosporin* or Cefalosporin* or Cefamandoleor* or Cefoperazone* or Cefazolin* or Cefdinir* or Cefepime* or Cefonicid* or Cefsulodin* or Ceftibuten* or Cefuroxime* or Cephacetrile* or Cefotaxime* or Cephalothin* or Cephapirin* or Cephalexin* or Cefaclor* or Cefadroxil* or Cefatrizine* or Cephaloglycin* or Cephradine* or Cephaloridine* or Ceftazidime* or Cephamycin* or Cefmetazole* or Cefotetan* or Cefoxitin*).tw,kf.	165066
95	*immunomodulating agent/	9770
96	*immunosuppressive agent/	20739
97	((immunomodula* adj2 (agent* or drug* or medication? or medicine? or compound? or therap*)) or immunomodulator? or immunotherap*).tw,kf.	328210
98	((immunosuppress* or immuno-suppress* or immunodepress*) adj2 (agent* or drug* or medication? or medicine? or compound? or substance? or therap*).tw,kf.	88981

99	*rivaroxaban/	7425
100	(rivaroxaban or assubex or ast-8294 or ast8294 or bay-59-7939 or bay-597939 or bay59-7939 or bay597939 or bs-112 or bs112 or dst-8294 or dst8294 or jnj-39039039 or jnj39039039 or kriva or naxat or rivaro or rivarolto or rivaxa or throsaben or xanirva or xarelto or xerdoxo or xindus).tw,kf.	16680
101	*cytokine receptor antagonist/	744
102	(interleukin inhibitor? or cytokine antagonist or cytokine receptor block* or interleukin receptor antagonist?).tw,kf.	310
103	((cilgavimab adj2 tixagevimab) or evusheld or "azd 1061 plus azd 8895" or "azd 1061/azd 8895" or azd-7442 or "azd 8895 plus azd 1061" or "azd 8895/azd 1061" or "azd1061 plus azd8895" or "azd1061/azd8895" or azd7442 or "azd8895 plus azd1061" or "azd8895/azd1061").tw,kf.	506
104	(itolizumab or alzumab or bmab-600 or bmab600 or eq-001 or eq001).tw,kf.	144
105	(dupilumab or bat-2406 or bat2406 or dupixent or regn-668 or regn668 or sar-231893 or sar231893).tw,kf.	5031
106	(pamrevlumab or fg-3019 or fg3019).tw,kf.	265
107	exp *monoclonal antibody/	291442
108	((monoclonal or clonal or hybridoma) adj3 antibod*).tw,kf.	282883
109	(bamlanivimab or etesevimab or "bamlanivimab/etesevimab" or "2423943-37-5" or "LY-3819253" or "LY-COV555" or "LY3819253" or "UNII-45I6OFJ8QH" or "WHO 11876" or "2423948-94-9" or "anti-Sars-cov-2 antibody JS016" or "CB6" or "JS016" or "LY COV016" or "LY-3832479" or "LY-COV016" or "LY3832479" or "NP005" or "UNII-N7Q9NLF11" or "WHO 11873").tw,kf.	720
110	(casirivimab or imdevimab or "casirivimab/imdevimab" or regen-cov or "REGN-COV2" or regn10933 or regn10987 or "anti-sars-cov-2 regn-cov2" or "2415933-42-3" or "REGN-10933" or "REGN10933" or "UNII-J0FI6WE1QN" or "WHO 11861" or "2415933-40-1" or "REGN-10987" or "REGN10987" or "UNII-2Z3DQD2JHM" or "WHO 11863").tw,kf.	696
111	*bamlanivimab plus etesevimab/ or *bamlanivimab/	233
112	*casirivimab plus imdevimab/ or *casirivimab/	316
113	*sotrovimab/	234
114	("Sotrovimab" or "2423014-07-5" or "GSK-4182136" or "GSK4182136" or "UNII-1MTK0BPN8V" or "VIR-7831" or "VIR7831").tw,kf.	527
115	*amubarvimab/	11
116	(amubarvimab or "BRII-196" or "BRII-198" or "DZIF-10c" or "BI 767551" or "SCTA01" or "Ty027" or "HLX70").tw,kf.	49
117	("C144-LS" or "C-135-LS" or "C144-LS/C-135-LS").tw,kf.	4
118	("COVI-GUARD" or "STI-1499").tw,kf.	5
119	("COVI-AMG" or "sti-2020").tw,kf.	3
120	*enuzovimab/	1
121	*plutavimab/	0
122	(enuzovimab or plutavimab).tw,kf.	0
123	*cilgavimab plus tixagevimab/	244

124	lomtegovimab/	7
125	*baricitinib/	1473
126	HFB30132A.tw,kf.	1
127	("ABBV-47D11" or "ABBV-2B04" or "AZD7442").tw,kf.	52
128	("BI 767551" or "DZIF-10c" or "COR-101").tw,kf.	8
129	(baricitinib or olumiant or incb28050 or ly3009104).tw,kf.	2834
130	((immune adj3 (sera or serum? or plasma)) or antisera or antiserum or immun#serum).tw,kf.	77757
131	exp *antiserum/	9535
132	exp *immunoglobulin/	164377
133	(immune* globulin? or immunoglobulin? or immunoglobulin?).tw,kf.	235781
134	exp *convalescent blood product/	1265
135	((convalescent adj2 (plasma or serum or sera)) or (plasma adj3 therap*)).tw,kf.	20928
136	*ibuprofen/	14745
137	(ibuprofen or abfen or "aches-n-pain" or "act-3" or actiprofen or "adex 200" or adex liqui-gels or advil or afebril or aktren or aktren spezial or algiasdin or algifor or algofen or algoflex or allipen or alvofen express or "am-fam 400" or anadin or anadvil or analgyl or anbifen or anco or andran or anflagen or antalgil or antarene or antiflam or apo-ibuprofen or aragel or "atril 300" or attritin or balkaprofen or berlistar or bestafen or betaprofen or bifen or bluton or brufanic or brufedol or brufen or brufort or brugesic or brumare or brumed or brupro or buburone or bufect or bufohexal or bupogesic or burana or butacortelone or butifen or caldolor or calprofen or cap-profen or cenbufen or codral period pain or combiflam or contraneural or cuprofen or dalsy or "dc 7034" or "dc7034" or "dg 7034" or "dg7034" or dibufen or "diffutab sr 600" or dimidon or dolan fp or dolgit or dolobene ibu or dolocyl or dolodolgit or dolofen-f or dolomax or dolormin or dolval or donjust b or dorival or druisel or easifon or ecoprofen or emflam or epobron or ergix douleur et fievre or eudorlin extra or exidol or expanfen or febratic or febyn or femapirin or fenalgic or fenbid or flamicon or flarin or froben dolore or galprofen or gelufene or gyno-neuralgin or halprin or haltran or hemagene tailleur or h-loniten or ib-100 or ibalgin or ibofen or ibosure or ibu or ibuberl or ibucalm or ibudak or ibudol or ibudolor or ibufarmalid or ibufen or ibuflam or ibufug or ibugel or ibugesic or ibukern or ibuleve or ibulgan or ibuloid or ibumetin or ibumousse or ibunin or ibupen or ibupirac or ibuprin or ibuprocin or ibuprofene or ibuprohm or ibuprom or iburon or ibusal or ibuspray or ibustar or ibusynth or ibutop or ibux or ibuxin or idyl sr or ifenin or infant's motrin or infibu or inflanor or inflanor forte or ipren or irfen or junifen or junipro or kenfen or kontraneural or lamidon or librofem or lidifen or liptan or lopane or malafene or maxagesic or "mcn r 1451" or medicol or medipren or mediprin or mensoton or midol or momentact or motrin or mynosedin or nagifen-d or napacetin or neobrufen or neobrufen retard or neroften or neutropain or nobfelon or nobgen or norflam-t or noritis or norton or novogent or novoprofen or nugin or nuprin or nureflex or nurofen or optifen or opturem or ostarin or ostofen or ozonol or paduden or panafen or pedea or pediacare fever or pediprofen or perdophen pediatrie or perofen or phorpain or phorpain gel or proartinal or profen or profeno or proff or proflex or proris or provin or provon or quadrax or rafen or ranofen or rapidophen or rapidophen forte or ratiadol or rebugen or renidon or reuvol or rhelafen or roidenin or rufen or rupan or saridon n or schufen or seclodin or solufen lidose or solvium or spalt or syntofene or tabalon or tab-profen or taskine or tatanal or tofen or trendar or umafen or unipro or upfen or uprofen or urem or viamal febbre e dolore or zafen or zofen).tw,kf.	28379
138	exp *serotonin uptake inhibitor/	123212
139	((serotonin or 5-Hydroxytryptamine or 5-HT) adj3 (reuptake-inhibitor? or uptake-inhibitor?)) or SSRI? or fluvoxamine or du-23000 or du23000 or fluoxamin? or fluroxamine?).tw,kf.	38100

140	exp *serotonin noradrenalin reuptake inhibitor/	81816
141	(SNRI* or SSNRI* or (((noradrenalin or norepinephrine) adj2 serotonin) or dual) adj3 (reuptake-inhibitor* or uptake-inhibitor*)).tw,kf.	5512
142	*citalopram/ or *escitalopram/ or *fluoxetine/ or *sertraline/ or *paroxetine/ or *desvenlafaxine/ or *duloxetine/ or *milnacipran/ or *milnacipran/ or *venlafaxine/	30876
143	(celexa or citalopram* or cytalopram or seropram or escitalopram* or lexapro or fluoxatin* or prozac or sarafer or altruline or sertraline or aremis or besitran or gladem or lustral or sealdin or zoloft or aropax or paroxetin* or paxil or seroxat or (desvenlafaxine* or ellefore or khedezla or o-desmethylvenlafaxine or o-norvenlafaxine or pristiq* or cymbalta or duloxetin* or dalcipran or fetzima or impulsor or ixel or jonica or levomilnacipran* or midalcipran or milnaneurax or savella* or toledomin* or dobupal or efexor or effexor or grz5rcb1qg or venlafaxin* or trevilor or vandral)).tw,kf.	55618
144	*metformin/	25732
145	(metformin or anj-900 or anj900 or apophage or aron or benofomin or dabex or denkaform or deson or dextin or diabetase or diabetformin or diabetmin or diabetosan or diabex or diafat or diaformin or diaformina or diametin or diamin or dianben or diformin or diformin retard or dimefor or dimethylbiguanide or dimethyldiguanide or dmgg or dybis or efb-0027 or efb0027 or eraphage or espa-formin or euform retard or fluamine or flumamine or fornidd or fortamet or glafornil or glibudon or glifage or gliguanid or glucaminol or glucofage or glucofago or glucoform or glucoformin or glucohexal or glucoless or glucomet or glucomin or glucomine or gluconil or Glucophage* or glucostop or glucotika or gludepatic or glufor or gluformin or glukophaghe or glumeformin or glumet or glumetza or glupa or glustress or glyciphage or glycomet or glycon or glycoran or glyformin or glymet or haurymellin or hipoglucin or islotin or jesocrin or juformin or la-6023 or la6023 or maformin or meglucon or megan or melbin or melformin or mellittin or merckformin or mescorit or metaformin or metfogamma or metfoliquid geriasan or metforal or metformax or metformin hydrochloride or metformina or metformine or methformin or metiguanide or metomin or metphormin or miformin or neoform or newmet or ndng or reglus-500 or riomet or risidon or rudimet or siamformet or siofor or thiabet or vimetrol or walaphage).tw,kf.	51563
146	*ivermectin/	5843
147	(ivermectin or bibovel or cardomec or cevamec or diapec or driponin or efacti or epimek or equimec or eqvalan or eqvalen or iveraxiro or ivercare or ivergalen or ivergelan or ivermectina or ivermectol or iverscab or ivertin or ivexterm or ivomec or k-237 or k237 or loutol or manburesa or mectizan or mk-933 or mk933 or oramec or posela or quanox gotas or revectina or romitu or scaball or scabioral or scatol or securu or sklice or soolantra or stromectol or vona or zulima).tw,kf.	10651
148	*resveratrol/	12069
149	(resveratrol or srt-501 or srt501).tw,kf.	22025
150	*naltrexone/	6658
151	(naltrexone* or abernil or addex-1000 or addex1000 or adepended or antaxon or antaxone or celupan or cyto-201 or cyto201 or depare or dependex or en-1639a or en1639a or ethylex or irt-103 or irt-104 or irt103 or irt104 or iodonal or n-cyclopropylmethylnoroxymorphone or nalerona or naloxex or naltrex or naltrel or naltrexin or nemexin or nodict or nutrexon or opnt-002 or opnt002 or phaltrexia or pti-901 or pti901 or regental or revez or revia or stat-200 or stat-201 or stat-205 or stat200 or stat201 or stat205 or tranalex or trexan or um-792 or um792 or vivitrex or vivitrol).tw,kf.	11184
152	*colchicine/	11853
153	(colchicin* or colchicum-dispert or colchily or colchimedio or colchiquim or colchisol or colchysat or colcine or colcrys or colctab or colgout or colrefuz or colperba or goutichine or goutnil or kolkicin or kolkisin or mitigare or mpc-004 or mpc004 or myinfla or tolchicine).tw,kf.	22957

154	or/26-153 [Drugs]	4995887
155	exp diet therapy/ or ((diet* or nutrition*) adj2 (advice* or therap* or counsel* or change* or intervention* or program*).tw,kf. or (dietitian* or nutritionist*).tw,kf.	503853
156	exp *stem cell transplantation/ or stem-cell transplant*.tw,kf.	164451
157	low level laser therapy/ or (photobiomodulation or photo-biomodulation or photo-bio-modulation or ((low-power or low-level or low-energy or low-intensity or soft or cold) adj2 (light or laser) adj2 (therap* or irradiat*) or (laser adj2 biostimulat*) or llit or ((laser adj2 phototherap*) or biostimulat*).tw,kf.	32822
158	*rehabilitation/ or muscle training/ or exp *neurorehabilitation/ or daily life activity/ or exp *kinesiotherapy/ or rehabilitation.tw,kf.	466815
159	((cognitive or neurologic*) adj4 (rehab* or motor-therap*).tw,kf.	9756
160	exp *self care/	35204
161	((patient or self) adj (manag* or treat*)) or self care).tw,kf.	145602
162	exp *patient attitude/ or *health literacy/ or *patient education/ or (patient* adj3 (educat* or knowledg* or literacy or literate or behavior* or behaviour* or attitud* or belief* or believ*).tw,kf.	307723
163	*self help/	6383
164	((self help or support*) adj3 (group? or club? or servic* or social*)) or (therap* adj3 (club? or group* or social*)).tw,kf.	210902
165	*disease management/ or ((manag* or cope or coping) adj3 (symptom* or disease* or condition* or pain or discomfort*).tw,kf.	245783
166	exp *exercise/ or exp *sport/ or exp *physical activity/ or *fitness/ or exp *physical medicine/	730625
167	("physical activit*" or walk* or pedestrian* or bicycl* or cycling or cyclist* or biking or bike* or "active lifestyle*" or "aerobic fitness" or "aerobic exercise*" or (running not "running water") or runner* or jog* or swim* or yoga or (physical* adj2 (activit* or active or exercise*)) or ((exercise* or fitness or aerobic*) adj2 (regimen* or training or intervention* or program* or class* or course* or train* or rehab*)).tw,kf.	781166
168	(physiotherap* or ((physical or physio) adj1 (therap* or treat*).tw,kf.	109656
169	*indigenous health care/	713
170	((indigenous or metis or aboriginal or inuit or (native adj (america* or alaska* or hawaii* or canad*)) or first nation* or first people*) and (healthcare or (health adj2 (care* or service* or program*)) or healing* or medic* or therap* or remed*).tw,kf.	28151
171	exp *alternative medicine/ or *traditional healer/ or exp *traditional medicine/ or exp *medicinal plant/ or *herbaceous agent/ or exp *plant medicinal product/	1075207
172	((alternat* or complementary or folk or traditional or holistic or chinese or african or tribal) adj2 (medic* or therap* or healing* or treat* or remed*).tw,kf.	304448
173	*hypnosis/ or (hypnotism or hypnosis or hypnotherapy).tw,kf.	12792
174	exp *acupuncture/ or *ayurvedic drug/	40680
175	(ayurved* or kampo or kanpo or acupunctur* or homeopath*).tw,kf.	61829

176	((botanical* or herb* or plant or plants or plantlet* or root or roots or natural) adj2 (drug? or extract? or healing* or ingredient? or medic* or preparation* or product or products or remedies or remedy* or supplement* or treat* or therap*).tw,kf.	289666
177	Rest/ or (rest or (avoid* adj2 (exercise* or exert*))).tw,kf.	278148
178	exp *mental health care/ or *social work/ or *psychosocial rehabilitation/	80958
179	((mental health or emotion* or psych* or wellbeing or well-being or stress* or wellness* or anxiet* or depress* or obsess* or ocd or mood* or posttrauma* or post-trauma* or ptsd or schizo* or personality disorder* or bipolar* or adhd or attention deficit* or addict*) adj3 (care or service? or support? or treat* or therap* or psychotherap* or counsel* or hotline*).tw,kf.	495624
180	(lifestyle adj3 (change* or intervention* or advice*)).tw,kf.	41042
181	exp *aftercare/ or *outpatient/ or *outpatient care/	90571
182	(aftercare or after care or follow-up care or referral?).tw,kf.	263437
183	*health care delivery/ or *nonbiological model/	70709
184	((healthcare or health care or clinical* or public health or community) adj4 (approach* or model? or service? or deliver* or system* or distribut* or framework? or guideline?)).tw,kf.	696265
185	(recovery adj2 (team* or clinic? or centre? or center? or model* or program*)).ti,ab,kf.	6596
186	((interdisciplin* or inter-disciplin* or cross-disciplin* or multidiscipline* or multi-disciplin*) adj3 (team* or clinic? or centre? or center? or model* or program*)).ti,ab,kf.	26991
187	((care or treatment or healthcare) adj2 (model* or path* or plan*)).ti,ab,kf.	291765
188	(care adj2 (coordinat* or co-ordinat*)).ti,ab,kf.	19983
189	(patient-centred care or patient-centered care or case manag*).ti,ab,kf.	36423
190	exp *patient referral/	23069
191	(refer* adj4 (specialist? or clinic? or therapy or therapist or counsel*)).tw,kf.	55507
192	or/155-191 [other interventions]	6096735
193	(12 or 25) and (154 or 192)	7071
194	3 or 193	7464
195	Clinical study/	165677
196	Case control study/	213259
197	Family study/	25787
198	Longitudinal study/	206445
199	Retrospective study/	1567259
200	Prospective study/	905333
201	Randomized controlled trials/	269111

202	200 not 201	894314
203	Cohort analysis/	1115562
204	(Cohort adj (study or studies)).mp.	500125
205	(Case control adj (study or studies)).tw.	173110
206	(follow up adj (study or studies)).tw.	75278
207	(observational adj (study or studies)).tw.	268223
208	(epidemiologic\$ adj (study or studies)).tw.	124520
209	(prospect* adj (study or studies)).tw.	329476
210	Longitudinal.tw.	457359
211	Retrospective.tw.	1311189
212	195 or 196 or 197 or 198 or 199 or 202 or 203 or 204 or 205 or 206 or 207 or 208 or 209 or 210 or 211	4396623
213	Randomized Controlled Trial/	806896
214	Randomized Controlled Trial (topic)/	269111
215	Controlled Clinical Trial/	472383
216	Controlled Clinical Trial (topic)/	13446
217	Randomization/	99045
218	Double Blind Procedure/	215796
219	Single Blind Procedure/	53564
220	placebo/	408881
221	Control Group/	110751
222	(random* or sham or placebo*).ti,ab,hw,kf.	2626827
223	((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf.	370375
224	((tripl* or trebl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf.	2294
225	(control* adj3 (study or studies or trial* or group*)).ti,ab,kf.	1777893
226	(Nonrandom* or non random* or non-random* or quasi-random* or quasirandom*).ti,ab,hw,kf.	72484
227	allocated.ti,ab,hw.	112944
228	((open label or open-label) adj5 (study or studies or trial*)).ti,ab,hw,kf.	90016
229	((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).ti,ab,hw,kf.	19297
230	(pragmatic study or pragmatic studies).ti,ab,hw,kf.	989
231	((pragmatic or practical) adj3 trial*).ti,ab,hw,kf.	9200

232	((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).ti,ab,hw,kf.	20839
233	(phase adj3 (III or "3") adj3 (study or studies or trial*)).ti,hw,kf.	133292
234	or/213-233	3879787
235	194 and (212 or 234)	3098
236	*case report/ or (case-stud* or case-report*).jw. or (case* and report*).ti.	616526
237	(editorial or conference abstract or conference paper or conference review).pt.	6624884
238	235 not (236 or 237)	2123
239	limit 238 to yr="2022 - 2024"	1777
240	(202205* or 202206* or 202207* or 202208* or 202209* or 20221* or 2023* or 2024*).dc,dd,dp.	3943805
241	239 and 240	1673
242	PMIDS FROM MEDLINE	761
243	241 not 242	1017

Table S9. Legend for database searches

/	At the end of a term or phrase, searches for term or phrase as a subject heading (index term).
*	"unlimited" truncation symbol. It substitutes for any number of characters at the end of a term or the root of a term, to retrieve plurals and variant spellings Before a subject heading, indicates that the subject heading is a main topic of the article
?	"wildcard" symbol. Substitutes for one or no characters
.ab	Abstract field code
ab. /freq=2	Searches for terms that are present at least twice in the abstract
.kf	Keywords assigned by authors
.mp	Multipurpose field code – searches in title, abstract, drug trade name (tn) and additional fields
.ti	Title field code
.tw	Text Word field code. In Embase includes title, abstract, and drug trade name (tn)
adj#	Operator that searches for terms adjacent within # number of words, in any order
exp	"Explodes" a subject heading by searching for the main subject heading and for all Narrower Terms